Data / Research funding / Lymphoma
Lymphoma: 667 NIH awards ($815.7M) to 168 organizations
667 NIH awards ($815.7M) in the NIH spending category Lymphoma, to 168 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 667 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $29,642,385 | September 12, 1997 | November 30, 2025 | RATHMELL, WENDY KIMRYN | reporter.nih.gov |
| MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE | NIH | National Cancer Institute | 2023 to 2025 | $22,579,077 | September 22, 2025 | September 21, 2027 | reporter.nih.gov | |
| The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study | NIH | National Cancer Institute | 2021 to 2025 | $10,080,862 | June 23, 2015 | March 31, 2026 | CERHAN, JAMES R | reporter.nih.gov |
| The 10,000 Families Cohort: a new study to understand the environmental causes of cancer | NIH | National Cancer Institute | 2023 to 2025 | $6,827,634 | September 24, 2021 | August 31, 2028 | POYNTER, JENNY N. | reporter.nih.gov |
| Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | NIH | National Cancer Institute | 2021 to 2025 | $6,371,380 | September 1, 2021 | June 30, 2027 | BROOKS, DAVID G | reporter.nih.gov |
| Metabolic gatekeepers in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $5,936,594 | April 1, 2016 | August 31, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA) | NIH | National Cancer Institute | 2024 to 2025 | $5,130,804 | September 1, 2024 | August 31, 2029 | FAN, RONG | reporter.nih.gov |
| Towards targeting the lymphoma microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $5,082,235 | September 1, 2020 | August 31, 2027 | WENDEL, HANS-GUIDO | reporter.nih.gov |
| From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $4,812,450 | September 12, 2023 | July 31, 2030 | DALLA-FAVERA, RICCARDO | reporter.nih.gov |
| The genetic and epigenetic etiology of progression from the precursor state to chronic lymphocytic leukemia (CLL) | NIH | National Cancer Institute | 2022 to 2025 | $4,109,575 | September 8, 2022 | August 31, 2027 | SLAGER, SUSAN L | reporter.nih.gov |
| Targeting Epigenetic Circuits in B-Cell Lymphomas | NIH | National Cancer Institute | 2021 to 2024 | $3,926,225 | September 13, 2018 | August 31, 2025 | MELNICK, ARI M. | reporter.nih.gov |
| Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors | NIH | National Cancer Institute | 2021 to 2025 | $3,743,381 | September 10, 2021 | August 31, 2027 | ZEBRACK, BRADLEY JAY | reporter.nih.gov |
| Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $3,557,045 | May 1, 2021 | April 30, 2024 | NIXON, DOUGLAS F | reporter.nih.gov |
| Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers | NIH | National Cancer Institute | 2021 to 2024 | $3,536,890 | April 1, 2020 | September 30, 2025 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells | NIH | National Cancer Institute | 2021 to 2025 | $3,469,484 | January 7, 2021 | December 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| The MYC Transcription Factor Network and the Path to Cancer | NIH | National Cancer Institute | 2021 to 2024 | $3,449,610 | September 1, 2018 | August 31, 2025 | EISENMAN, ROBERT NEIL | reporter.nih.gov |
| B cell determinants of EBV latency (supplement) | NIH | National Cancer Institute | 2022 to 2025 | $3,376,443 | September 9, 2022 | August 31, 2027 | CESARMAN, ETHEL | reporter.nih.gov |
| Germline and Somatic Genomic Studies in CLL | NIH | National Cancer Institute | 2021 to 2025 | $3,266,846 | July 1, 2021 | September 30, 2026 | SLAGER, SUSAN L | reporter.nih.gov |
| Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients | NIH | National Cancer Institute | 2021 to 2025 | $3,235,983 | July 1, 2020 | June 30, 2027 | LAROCCA, CECILIA | reporter.nih.gov |
| Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,218,917 | August 15, 2015 | June 30, 2026 | JENQ, ROBERT | reporter.nih.gov |
| Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $3,211,729 | March 4, 2021 | February 28, 2026 | ALIZADEH, ASH ARASH | reporter.nih.gov |
| Pre-malignant mutation landscape and risk factors for progression to hematologic cancers | NIH | National Cancer Institute | 2021 to 2025 | $3,207,103 | April 1, 2021 | March 31, 2027 | DESAI, PINKAL | reporter.nih.gov |
| Outcomes for CLL patients treated with novel therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,205,518 | September 15, 2021 | August 31, 2026 | KAY, NEIL E | reporter.nih.gov |
| Pacritinib in rel/refr T-cell lymphomas | NIH | National Cancer Institute | 2021 to 2025 | $3,194,893 | September 1, 2021 | August 31, 2027 | WILCOX, RYAN A | reporter.nih.gov |
| Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL) | NIH | National Cancer Institute | 2021 to 2025 | $3,143,480 | April 1, 2021 | March 31, 2027 | BROWN, JENNIFER R | reporter.nih.gov |
| TYK2 Fusions in Lymphoma | NIH | National Cancer Institute | 2025 | $3,111,184 | September 1, 2025 | August 31, 2029 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease | NIH | National Cancer Institute | 2023 to 2025 | $3,096,663 | September 1, 2023 | August 31, 2028 | MARTINEZ, OLIVIA M | reporter.nih.gov |
| Leveraging canine spontaneous cancer to optimize the power of blood biopsy | NIH | National Cancer Institute | 2021 to 2025 | $3,095,555 | June 7, 2021 | May 31, 2027 | KARLSSON, ELINOR | reporter.nih.gov |
| Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV | NIH | National Cancer Institute | 2022 to 2025 | $3,019,287 | September 12, 2022 | August 31, 2027 | BHADURI-MCINTOSH, SUMITA | reporter.nih.gov |
| Cbfb in RORgt-regulated T cell function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,010,210 | May 1, 2014 | May 31, 2029 | SUN, ZUOMING | reporter.nih.gov |
| Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,996,021 | June 1, 2011 | January 31, 2027 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Discovery and Characterization of Genetic Risk Loci in Sjogren's Syndrome | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $2,957,132 | September 7, 2020 | August 31, 2025 | LESSARD, CHRISTOPHER J | reporter.nih.gov |
| Functions and mechanisms of transcriptional coactivator OCA-B in B cell development and lymphomagenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,950,108 | December 12, 2019 | November 30, 2025 | ROEDER, ROBERT G | reporter.nih.gov |
| Modeling Multi-Source Data in Hodgkin Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,935,832 | March 1, 2022 | February 28, 2027 | PARSONS, SUSAN KENYON | reporter.nih.gov |
| Personalized Risk Prediction to Reduce Cardiovascular Disease in Childhood Cancer Survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,933,453 | July 15, 2022 | April 30, 2027 | HOWELL, REBECCA MAUREEN | reporter.nih.gov |
| Molecular Mechanisms of Drug Resistance in Primary Brain Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,926,627 | January 1, 2018 | November 30, 2025 | MELLINGHOFF, INGO K | reporter.nih.gov |
| Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | NIH | National Cancer Institute | 2022 to 2025 | $2,917,317 | December 9, 2021 | November 30, 2026 | KENDERIAN, SAAD J. | reporter.nih.gov |
| The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,895,508 | December 12, 2019 | January 31, 2025 | SAMAYOA REYES, GABRIELA M | reporter.nih.gov |
| A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity | NIH | National Cancer Institute | 2022 to 2025 | $2,770,577 | February 24, 2022 | January 31, 2027 | DIEFENBACH, CATHERINE SIBYL | reporter.nih.gov |
| Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | NIH | National Cancer Institute | 2022 to 2025 | $2,766,745 | July 1, 2022 | June 30, 2027 | JIM, HEATHER S.L. | reporter.nih.gov |
| Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,766,158 | September 1, 2023 | August 31, 2028 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| Regulation of anti-tumor immunity by HDAC11 | NIH | National Cancer Institute | 2021 to 2024 | $2,757,378 | June 1, 2020 | May 31, 2026 | SETO, EDWARD | reporter.nih.gov |
| Rhesus HHV-8 homologue in AIDS-related malignancies | NIH | National Cancer Institute | 2021 to 2024 | $2,752,636 | July 1, 1997 | July 31, 2025 | WONG, SCOTT W | reporter.nih.gov |
| Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel | NIH | National Cancer Institute | 2021 to 2024 | $2,726,050 | September 1, 2020 | May 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies | NIH | National Cancer Institute | 2021 to 2024 | $2,720,622 | July 1, 2020 | June 30, 2025 | WANG, JIN | reporter.nih.gov |
| BAF complex deregulation in lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,711,912 | August 2, 2022 | July 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Spatially resolved, single cell biomarkers of B cell lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,690,152 | August 1, 2022 | July 31, 2027 | MERCHANT, AKIL | reporter.nih.gov |
| InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies. | NIH | National Cancer Institute | 2021 to 2025 | $2,685,053 | September 3, 2021 | August 31, 2026 | MCKAY, JAMES DOWLING | reporter.nih.gov |
| BAFF-R CAR T cell therapy for ALL | NIH | National Cancer Institute | 2022 to 2025 | $2,663,058 | April 18, 2022 | March 31, 2027 | WANG, XIULI | reporter.nih.gov |
| Genetic and Biochemical Studies of KSHV LANA | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,646,919 | April 1, 2020 | March 31, 2026 | KAYE, KENNETH M | reporter.nih.gov |
| Targeted Therapies for Lymphoid Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,642,763 | April 1, 2013 | January 31, 2026 | WOYACH, JENNIFER A. | reporter.nih.gov |
| Tumor suppressor reprogramming by EBV through post-translational modification | NIH | National Cancer Institute | 2022 to 2025 | $2,640,070 | September 1, 2022 | August 31, 2028 | ROBERTSON, ERLE S. | reporter.nih.gov |
| Translation of a novel combination therapy approach for non-Hodgkin lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,620,855 | September 1, 2022 | August 31, 2027 | NAIK, SHRUTHI | reporter.nih.gov |
| Essential role of the cyclin-G associated kinase (GAK) in diffuse large B-cell lymphoma progression | NIH | National Cancer Institute | 2025 | $2,617,975 | August 1, 2025 | July 31, 2029 | SCHATZ, JONATHAN H | reporter.nih.gov |
| Targeting Latency Switch in EBV+ Lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $2,611,281 | July 1, 2022 | June 30, 2027 | ROTH, LISA GIULINO | reporter.nih.gov |
| Viral Noncoding RNAs and Cell Transformation | NIH | National Cancer Institute | 2022 to 2025 | $2,579,432 | January 20, 2022 | December 31, 2026 | STEITZ, JOAN A. | reporter.nih.gov |
| COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children | NIH | National Cancer Institute | 2022 to 2025 | $2,523,182 | March 1, 2022 | February 28, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,499,820 | September 9, 2022 | August 31, 2028 | WANG, XIULI | reporter.nih.gov |
| Tailoring CAR T cell therapy for Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,475,444 | July 1, 2020 | June 30, 2026 | SAVOLDO, BARBARA | reporter.nih.gov |
| Diagnosis of indeterminate brain lesions using MRI-based machine learning and polygenic risk models | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,473,627 | August 15, 2020 | December 31, 2025 | ECKEL PASSOW, JEANETTE E | reporter.nih.gov |
| Genome Architecture in Human Germinal Center B Cell Development, Malignancy, and Somatic Hypermutation | NIH | National Cancer Institute | 2021 to 2024 | $2,471,907 | September 15, 2020 | August 31, 2025 | SCHATZ, DAVID G. | reporter.nih.gov |
| SYK and ZAP70 kinases in lymphocyte selection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,450,839 | February 1, 2022 | January 31, 2027 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Defining and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $2,415,701 | September 19, 2022 | August 31, 2027 | LUFTIG, MICAH ALAN | reporter.nih.gov |
| Metabolic Imaging of Targeted Therapies in Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,412,354 | January 17, 2022 | December 31, 2026 | NATH, KAVINDRA | reporter.nih.gov |
| Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,410,423 | August 1, 2021 | July 31, 2026 | IQBAL, JAVEED | reporter.nih.gov |
| DISSECTING THE ROLE OF PRDM15 IN NORMAL HEMATOPOIESIS AND B-CELL MALIGNANCIES | NIH | National Cancer Institute | 2021 to 2025 | $2,407,764 | December 9, 2020 | November 30, 2025 | GUCCIONE, ERNESTO | reporter.nih.gov |
| LTBR CARs as next-generation therapies for R/R lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $2,404,689 | April 10, 2023 | March 31, 2028 | SANJANA, NEVILLE | reporter.nih.gov |
| Escape from CAR T surveillance through lineage plasticity | NIH | National Cancer Institute | 2022 to 2025 | $2,388,454 | April 1, 2022 | March 31, 2027 | ERNST, PATRICIA | reporter.nih.gov |
| (PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment | NIH | National Cancer Institute | 2021 to 2024 | $2,387,284 | May 15, 2020 | April 30, 2026 | CESARMAN, ETHEL | reporter.nih.gov |
| Mechanistic Elucidation of Class Switch Recombination and Somatic Hypermutation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,375,342 | July 1, 2009 | January 31, 2026 | CHAUDHURI, JAYANTA | reporter.nih.gov |
| Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,374,490 | July 10, 2014 | June 30, 2025 | MOORMANN, ANN M | reporter.nih.gov |
| Development of A HTLV-1 Vaccine | NIH | National Cancer Institute | 2021 to 2024 | $2,357,214 | March 3, 2021 | February 28, 2026 | BARBER, GLEN N. | reporter.nih.gov |
| Role of the stromal microenvironment in B-cell lymphoma progression and immune escape | NIH | National Cancer Institute | 2021 to 2024 | $2,350,136 | December 1, 2019 | November 30, 2025 | CERCHIETTI, LEANDRO C | reporter.nih.gov |
| Models and methods for automatically measuring disease body-wide and staging disease via FDG-PET/CT in Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,339,662 | August 12, 2021 | July 31, 2025 | UDUPA, JAYARAM K | reporter.nih.gov |
| Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation | NIH | National Cancer Institute | 2021 to 2025 | $2,339,012 | September 1, 2011 | July 31, 2026 | LUFTIG, MICAH ALAN | reporter.nih.gov |
| Dissecting immune surveillance to gammaherpesviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,328,052 | September 16, 2020 | August 31, 2025 | USHERWOOD, EDWARD J | reporter.nih.gov |
| Mechanisms regulating KSHV transcription elongation and termination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,318,808 | June 10, 2021 | May 31, 2027 | CONRAD, NICHOLAS K | reporter.nih.gov |
| The role of N6-methyladenosine RNA modification in programmed and aberrant DNA mutagenesis in B cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,301,592 | September 9, 2020 | November 30, 2029 | BASU, UTTIYA | reporter.nih.gov |
| Causal Representation Learning for the Spatial Analysis of Transcriptomic and Imaging Data in Tissue Contexts | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $2,298,000 | September 15, 2022 | August 31, 2027 | UHLER, CAROLINE | reporter.nih.gov |
| Novel CAR T cell engineering strategies for effective eradication of solid and liquid tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,291,623 | September 20, 2019 | May 31, 2030 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Enabling AI-based Mouse Genetic Discovery | NIH | Office of the Director, National Institutes of Health | 2023 to 2025 | $2,289,285 | August 1, 2023 | July 31, 2027 | PELTZ, GARY A | reporter.nih.gov |
| Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $2,289,208 | May 1, 2021 | April 30, 2027 | NIXON, DOUGLAS F | reporter.nih.gov |
| Regulation of EBV Latency by Purine Metabolism and Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,287,875 | May 19, 2021 | April 30, 2027 | TEMPERA, ITALO | reporter.nih.gov |
| Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,273,181 | April 1, 2022 | March 31, 2027 | ALINARI, LAPO | reporter.nih.gov |
| XBP1 Inhibition and STING activation for the treatment of cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,273,099 | April 8, 2022 | March 31, 2027 | HU, CHIH-CHI ANDREW | reporter.nih.gov |
| Overcoming ibrutinib resistance in mantle cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,239,026 | February 1, 2021 | January 31, 2026 | DANILOV, ALEXEY V. | reporter.nih.gov |
| Targeting Epstein-Barr Virus Super-Enhancer | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,237,500 | March 1, 2016 | March 31, 2026 | ZHAO, BO | reporter.nih.gov |
| Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,226,458 | April 1, 2021 | March 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Gammaherpesvirus miRNA suppression of EWSR1 in GC B cell infection and lymphomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,206,513 | August 1, 2021 | July 31, 2026 | TIBBETTS, SCOTT A. | reporter.nih.gov |
| A high-throughput platform to identify selective allosteric inhibitors of the PLC-y isozymes | NIH | National Cancer Institute | 2021 to 2024 | $2,198,247 | May 1, 2021 | April 30, 2026 | ZHANG, QISHENG | reporter.nih.gov |
| Targeting SOX11 in Mantle Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,197,928 | September 1, 2020 | November 30, 2025 | PAREKH, SAMIR | reporter.nih.gov |
| The role of DNA-PKcs in DNA repair, lymphocyte development, RNA metabolism and tumor suppression | NIH | National Cancer Institute | 2022 to 2025 | $2,194,376 | July 1, 2022 | June 30, 2027 | ZHA, SHAN | reporter.nih.gov |
| Role of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapies | NIH | National Cancer Institute | 2021 to 2024 | $2,183,689 | July 1, 2020 | June 30, 2026 | CERCHIETTI, LEANDRO C | reporter.nih.gov |
| Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study | NIH | National Cancer Institute | 2022 to 2024 | $2,178,209 | January 1, 2020 | December 31, 2025 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway Inhibitors | NIH | National Cancer Institute | 2022 to 2025 | $2,169,356 | August 1, 2022 | July 31, 2027 | SINGH, ANKUR | reporter.nih.gov |
| Exploring the potential of TET inhibition in cancer immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,169,214 | July 1, 2020 | June 30, 2025 | RAO, ANJANA | reporter.nih.gov |
| New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,168,990 | June 1, 2020 | May 31, 2025 | CLEVELAND, JOHN L. | reporter.nih.gov |
| Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,164,975 | December 1, 2020 | November 30, 2025 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| The transcription factor c-MYC in lymphocyte expansion and restriction of stemness | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,159,884 | September 25, 2017 | July 31, 2028 | EGAWA, TAKESHI | reporter.nih.gov |
| Role of S.aureus in Cutaneous T Cell Lymphoma Pathogenesis | NIH | National Cancer Institute | 2022 to 2025 | $2,150,022 | May 10, 2022 | April 30, 2027 | KORALOV, SERGEI BORISOVICH | reporter.nih.gov |
| Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture | NIH | National Cancer Institute | 2021 to 2024 | $2,149,252 | July 7, 2021 | January 1, 2025 | KREBS, SIMONE | reporter.nih.gov |
| Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers | NIH | National Cancer Institute | 2022 to 2025 | $2,147,095 | September 7, 2022 | July 31, 2027 | SALVINO, JOSEPH M | reporter.nih.gov |
| Site-Specific Recombination in Human Health & Disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,145,000 | June 1, 2016 | May 31, 2027 | LIEBER, MICHAEL R | reporter.nih.gov |
| Unraveling the Pathophysiology of Neurotoxicity Induced by CAR T-cells | NIH | National Cancer Institute | 2022 to 2025 | $2,131,216 | August 8, 2022 | July 31, 2027 | PENNELL, CHRISTOPHER A | reporter.nih.gov |
| Th17 generation, action and therapeutic relevance in chronic lymphocytic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,127,395 | December 1, 2019 | November 30, 2025 | CHIORAZZI, NICHOLAS | reporter.nih.gov |
| RNA-directed targeting of AID in immunity and cancer | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,124,000 | February 1, 2016 | June 30, 2027 | CHAUDHURI, JAYANTA | reporter.nih.gov |
| A novel strategy for transcriptional reprogramming of lymphoid leukemia cells | NIH | National Cancer Institute | 2022 to 2025 | $2,123,519 | January 1, 2022 | December 31, 2026 | CALABRETTA, BRUNO | reporter.nih.gov |
| Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,108,871 | June 1, 2021 | May 31, 2027 | YANG, YIBIN | reporter.nih.gov |
| The 10,000 Families Cohort: a new study to understand the environmental causes of cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,106,878 | September 24, 2021 | August 31, 2023 | POYNTER, JENNY N. | reporter.nih.gov |
| Lymph node-targeted multistage chemoimmunotherapy for lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,094,096 | April 1, 2020 | March 31, 2026 | THOMAS, SUSAN NAPIER | reporter.nih.gov |
| New Materials to Deliver mRNA: Applications in Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,075,015 | August 13, 2020 | April 30, 2025 | WAYMOUTH, ROBERT M. | reporter.nih.gov |
| MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER | NIH | National Cancer Institute | 2022 to 2025 | $2,073,174 | April 12, 2022 | March 31, 2027 | RUELLA, MARCO | reporter.nih.gov |
| Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $2,068,451 | March 13, 2023 | February 29, 2028 | KHARAS, MICHAEL | reporter.nih.gov |
| Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,064,042 | July 16, 2015 | November 30, 2026 | CHIARLE, ROBERTO | reporter.nih.gov |
| Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva | NIH | National Cancer Institute | 2023 to 2025 | $2,053,910 | September 8, 2023 | August 31, 2028 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy | NIH | National Cancer Institute | 2021 to 2023 | $2,047,877 | December 1, 2018 | November 30, 2024 | ROSEN, STEVEN TERRY | reporter.nih.gov |
| Mechanism of Eukaryotic Environmental Mutagenesis | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $2,037,163 | September 15, 2017 | May 31, 2026 | WALKER, GRAHAM C | reporter.nih.gov |
| GDANII_DLBCL cohort analysis and cloud costs | NIH | National Cancer Institute | 2021 to 2025 | $2,032,755 | December 1, 2024 | August 31, 2025 | GETZ, GAD A | reporter.nih.gov |
| Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,022,453 | April 6, 2021 | March 31, 2027 | YANG, YIBIN | reporter.nih.gov |
| Therapeutic targeting of SIRT3 for aggressive and refractory lymphomas | NIH | National Cancer Institute | 2023 to 2025 | $2,005,584 | March 2, 2023 | February 29, 2028 | LI, MENG | reporter.nih.gov |
| Central tolerance mechanisms in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,003,674 | June 1, 2011 | June 30, 2027 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Treg-depleting immunotherapy | NIH | National Cancer Institute | 2021 to 2022 | $2,000,000 | September 7, 2020 | September 30, 2024 | SUZDAK, PETER DAVID | reporter.nih.gov |
| Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients | NIH | National Cancer Institute | 2022 to 2023 | $1,999,998 | June 10, 2022 | April 30, 2024 | DEISHER, THERESA | reporter.nih.gov |
| CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients | NIH | National Cancer Institute | 2024 to 2025 | $1,999,990 | September 20, 2024 | August 31, 2026 | BERTOLINO, ARTHUR P | reporter.nih.gov |
| Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies | NIH | National Cancer Institute | 2024 to 2025 | $1,999,703 | September 1, 2024 | August 31, 2027 | HEIN, SARAH MARIE | reporter.nih.gov |
| A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL | NIH | National Cancer Institute | 2021 to 2022 | $1,998,672 | September 16, 2021 | August 31, 2023 | LITCHMAN, MANUEL | reporter.nih.gov |
| An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia | NIH | National Cancer Institute | 2021 to 2023 | $1,994,489 | September 1, 2021 | August 31, 2024 | LONGCOR, JARROD | reporter.nih.gov |
| Molecular control of germinal center selection and affinity maturation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,993,832 | August 15, 2018 | May 31, 2029 | VICTORA, GABRIEL D | reporter.nih.gov |
| Molecular mechanisms governing the ubiquitination signaling during KSHV cell entry and tumorigenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,992,560 | July 1, 2021 | June 30, 2027 | SHEMBADE, NOULA DATTU | reporter.nih.gov |
| The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $1,989,049 | July 1, 2021 | June 30, 2026 | NGO, VU NGUYEN | reporter.nih.gov |
| Role of novel onco-histone mutations in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2023 | $1,967,972 | August 1, 2019 | July 31, 2025 | CESARMAN, ETHEL | reporter.nih.gov |
| Regulation of B cell signaling in autoimmunity by TRAF3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,964,463 | August 1, 2021 | July 31, 2026 | BISHOP, GAIL A. | reporter.nih.gov |
| Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition | NIH | National Cancer Institute | 2021 to 2024 | $1,963,552 | March 9, 2020 | February 28, 2026 | NATH, KAVINDRA | reporter.nih.gov |
| Epigenomic Control of KSHV Latency | NIH | National Cancer Institute | 2021 to 2025 | $1,945,305 | April 1, 2006 | June 30, 2028 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $1,944,040 | March 1, 2020 | February 28, 2025 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| (PQ4) Role of HIV-induced PLK1 Activation in Regulation of gamma-Herpesvirus Reservoirs in Lymphocytes | NIH | National Cancer Institute | 2021 to 2025 | $1,939,971 | May 11, 2021 | April 30, 2027 | SANTOSO, NETTY G | reporter.nih.gov |
| Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI | NIH | National Cancer Institute | 2023 to 2025 | $1,935,453 | December 16, 2022 | November 30, 2027 | LI, YONG | reporter.nih.gov |
| Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,923,862 | August 14, 2019 | January 31, 2025 | LUFTIG, MICAH A. | reporter.nih.gov |
| Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,920,168 | August 9, 2019 | July 31, 2025 | MCGUIRE, ANDREW | reporter.nih.gov |
| Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $1,917,273 | July 20, 2022 | June 30, 2027 | ORLOWSKI, ROBERT ZYGMUNT | reporter.nih.gov |
| The role of NUDT16 in DNA damage response and tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,900,364 | December 1, 2018 | July 31, 2029 | GONG, ZIHUA | reporter.nih.gov |
| Mechanisms of Lymphomagenesis of Skin Resident Gamma Delta T cells | NIH | National Cancer Institute | 2022 to 2025 | $1,898,706 | December 13, 2021 | November 30, 2026 | LE POOLE, I. CAROLINE | reporter.nih.gov |
| Integration of germline and tumor genomes in CLL | NIH | National Cancer Institute | 2021 to 2023 | $1,895,188 | December 6, 2018 | May 31, 2024 | SLAGER, SUSAN L | reporter.nih.gov |
| Non-canonical Wnt-Receptor Signaling and Targeted Therapies | NIH | National Cancer Institute | 2021 to 2023 | $1,888,486 | April 15, 2019 | March 31, 2025 | KIPPS, THOMAS J | reporter.nih.gov |
| Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination | NIH | National Cancer Institute | 2021 to 2025 | $1,875,709 | December 1, 2024 | November 30, 2026 | BRODY, JOSHUA D | reporter.nih.gov |
| Role of CREBBP missense mutations in lymphomagenesis | NIH | National Cancer Institute | 2022 to 2025 | $1,867,100 | January 1, 2022 | December 31, 2026 | PASQUALUCCI, LAURA | reporter.nih.gov |
| Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,861,249 | July 1, 2023 | August 31, 2027 | GIBBONS, HUNTER RAMSDELL | reporter.nih.gov |
| Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,860,326 | April 1, 2023 | March 31, 2028 | SIMPSON, RICHARD J | reporter.nih.gov |
| Understanding Richter's Transformation in the targeted therapies era | NIH | National Cancer Institute | 2021 to 2024 | $1,854,920 | September 11, 2020 | May 31, 2025 | LAPALOMBELLA, ROSA | reporter.nih.gov |
| Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,852,168 | December 1, 2019 | November 30, 2025 | POMERANTZ, JOEL L | reporter.nih.gov |
| Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic | NIH | National Cancer Institute | 2025 | $1,847,485 | September 19, 2025 | August 31, 2029 | REZVANI, KATY | reporter.nih.gov |
| Epstein-Barr virus LMP1 mediated oncogenicity | NIH | National Cancer Institute | 2021 to 2025 | $1,836,181 | September 19, 2019 | March 31, 2030 | GEWURZ, BENJAMIN ELISON | reporter.nih.gov |
| Intravenous VSV virotherapy in lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,828,271 | May 11, 2023 | April 30, 2028 | PENG, KAH-WHYE | reporter.nih.gov |
| Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures | NIH | National Cancer Institute | 2021 to 2025 | $1,827,310 | September 20, 2021 | August 31, 2027 | IQBAL, JAVEED | reporter.nih.gov |
| Role and Mechanisms of VAV1 alterations in Peripheral T-cell Lymphomas | NIH | National Cancer Institute | 2021 to 2025 | $1,819,525 | July 1, 2021 | May 31, 2027 | PALOMERO, TERESA | reporter.nih.gov |
| Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies | NIH | National Cancer Institute | 2021 to 2023 | $1,817,793 | February 1, 2019 | January 31, 2025 | COLEVAS, A. DIMITRIOS | reporter.nih.gov |
| Linking insertional mutagenesis and cell function to improve CAR T cell therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,813,460 | June 1, 2019 | April 30, 2024 | BUSHMAN, FREDERIC D | reporter.nih.gov |
| Exposing synthetic lethal vulnerabilities in EBV-positive AIDS-NHL through novel replication dependency factors | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $1,804,864 | September 4, 2023 | August 31, 2028 | BHADURI-MCINTOSH, SUMITA | reporter.nih.gov |
| Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,797,355 | July 21, 2023 | June 30, 2028 | VASU, SUMITHIRA | reporter.nih.gov |
| Targeting GSK3B in refractory B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,794,818 | July 19, 2023 | June 30, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| EBNA1 Inhibitor for Treatment of EBV-positive DLBCL | NIH | National Cancer Institute | 2023 to 2025 | $1,785,789 | July 7, 2023 | June 30, 2028 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Single-cell characterization of tumor and microenvironment co-evolution in Peripheral T-cell Lymphomas | NIH | National Cancer Institute | 2021 to 2023 | $1,779,750 | August 21, 2019 | July 31, 2024 | RABADAN, RAUL | reporter.nih.gov |
| Therapeutic implication of CD38 in CLL | NIH | National Cancer Institute | 2021 to 2023 | $1,773,312 | September 4, 2019 | August 31, 2025 | CHINI, EDUARDO N | reporter.nih.gov |
| Scaling Lymphoma Diagnosis: A Cost-Effective Gene Expression Assay for Broad Implementation | NIH | National Cancer Institute | 2025 | $1,770,000 | September 17, 2025 | August 31, 2027 | BRIERCHECK, EDWARD | reporter.nih.gov |
| Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,768,990 | July 4, 2019 | June 30, 2025 | RUBENSTEIN, JAMES LOUIS | reporter.nih.gov |
| Metagenomic shotgun microbial sequencing in post-transplant lymphoproliferative disorders (PTLD-MSMS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,764,549 | June 10, 2019 | May 31, 2025 | WYLIE, KRISTINE M. | reporter.nih.gov |
| The Biology of Mutant STAT6 in Follicular Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,759,271 | September 1, 2022 | August 31, 2027 | MALEK, SAMI NIMER | reporter.nih.gov |
| Lymphoid Experimental Therapeutics Platform to Study Cooperative Signaling inHuman Lymphomas | NIH | National Cancer Institute | 2021 to 2024 | $1,752,723 | July 1, 2020 | June 30, 2026 | SINGH, ANKUR | reporter.nih.gov |
| Anti-tumor potential of temperature-sensitive p53 mutants | NIH | National Cancer Institute | 2021 to 2025 | $1,747,237 | March 1, 2021 | February 28, 2027 | CHEN, JIANDONG | reporter.nih.gov |
| Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $1,746,152 | September 20, 2022 | July 31, 2027 | JOHANNSEN, ERIC C. | reporter.nih.gov |
| Genomic biomarkers of splenic lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,743,045 | October 1, 2022 | November 30, 2026 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Gammaherpesvirus protein kinase: a master manipulator of the host during chronic infection. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,730,785 | June 22, 2022 | May 31, 2028 | TARAKANOVA, VERA L. | reporter.nih.gov |
| Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL | NIH | National Cancer Institute | 2023 to 2024 | $1,730,616 | September 9, 2020 | July 31, 2025 | DESAI, AVINASH | reporter.nih.gov |
| Molecular Basis of KSHV oncogenesis | NIH | National Cancer Institute | 2021 to 2022 | $1,726,428 | March 1, 2016 | February 28, 2023 | JUNG, JAE U | reporter.nih.gov |
| Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies | NIH | National Cancer Institute | 2022 to 2025 | $1,713,034 | August 1, 2022 | July 31, 2027 | CARRASCO, RUBEN D | reporter.nih.gov |
| Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH) | NIH | National Cancer Institute | 2024 to 2025 | $1,709,513 | September 1, 2023 | August 31, 2028 | DHARNIDHARKA, VIKAS R. | reporter.nih.gov |
| Metabolic adaptation in lymphoid malignancies | NIH | National Cancer Institute | 2021 to 2024 | $1,709,232 | December 1, 2019 | November 30, 2025 | ZHANG, JI | reporter.nih.gov |
| Preventing follicular lymphoma progression and transformation through precision therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,702,539 | June 1, 2022 | December 31, 2025 | BEGUELIN, WENDY | reporter.nih.gov |
| Novel functions of CDK6 in T-cell leukemia progression | NIH | National Cancer Institute | 2021 to 2025 | $1,701,837 | August 1, 2021 | July 31, 2026 | WANG, HAIZHEN | reporter.nih.gov |
| Cell Intrinsic Immune Control of KSHV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,698,320 | December 1, 2019 | November 30, 2025 | KARIJOLICH, JOHN | reporter.nih.gov |
| (PQ#2) Transposable element-mediated gene regulation in KSHV-associated cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,698,320 | April 1, 2020 | March 31, 2026 | KARIJOLICH, JOHN | reporter.nih.gov |
| Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach | NIH | National Cancer Institute | 2021 to 2024 | $1,694,221 | July 9, 2012 | November 30, 2025 | PELLECCHIA, MAURIZIO | reporter.nih.gov |
| BCLW in lymphoma survival and resistance to targeted BCL2 family therapies | NIH | National Cancer Institute | 2021 to 2025 | $1,683,312 | December 1, 2019 | November 30, 2025 | EISCHEN, CHRISTINE M. | reporter.nih.gov |
| Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,679,695 | March 15, 2019 | February 28, 2025 | QUERFELD, CHRISTIANE | reporter.nih.gov |
| Mutational cooperativity in TET2-associated hematological malignancies. | NIH | National Cancer Institute | 2021 to 2025 | $1,679,433 | April 1, 2021 | March 31, 2026 | HUANG, YUN | reporter.nih.gov |
| Programmed splicing derangement as new EBV host cell shut-off mechanism | NIH | National Cancer Institute | 2022 to 2025 | $1,676,014 | April 1, 2022 | March 31, 2027 | FLEMINGTON, ERIK K | reporter.nih.gov |
| Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host | NIH | National Cancer Institute | 2021 to 2022 | $1,669,656 | September 2, 2016 | August 31, 2023 | LEVY, RONALD | reporter.nih.gov |
| Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $1,669,583 | September 1, 2020 | May 31, 2026 | CLARK, RACHAEL ANN | reporter.nih.gov |
| Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $1,669,514 | April 1, 2020 | March 31, 2025 | WANG, LILI | reporter.nih.gov |
| MALT1 as a rational therapeutic target in African American ancestry patients with DLBCL | NIH | National Cancer Institute | 2023 to 2025 | $1,665,977 | September 14, 2023 | August 31, 2028 | ZAPPASODI, ROBERTA | reporter.nih.gov |
| Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,664,746 | April 1, 2005 | December 31, 2026 | RIDDELL, STANLEY R. | reporter.nih.gov |
| In situ atomic structures of the Kaposi's sarcoma-associated herpesvirus portal-terminase complex and glycoproteins | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $1,663,681 | December 1, 2015 | August 31, 2025 | ZHOU, Z HONG | reporter.nih.gov |
| A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,660,806 | August 1, 2019 | July 31, 2024 | ALIZADEH, ASH ARASH | reporter.nih.gov |
| EBV reactivation causes widespread host de novo promoter transcription and transcriptional interference | NIH | National Cancer Institute | 2022 to 2025 | $1,647,874 | July 1, 2022 | June 30, 2027 | FLEMINGTON, ERIK K | reporter.nih.gov |
| Epigenetic Mechanisms Underpinning Mantle Cell Lymphoma Sensitivity and Resistance to Notch Inhibitors | NIH | National Cancer Institute | 2022 to 2025 | $1,644,828 | April 1, 2022 | March 31, 2027 | FARYABI, ROBERT BABAK | reporter.nih.gov |
| The Role of Pacs1-Wdr37 inLymphocyte Quiescence and Survival | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,627,700 | February 9, 2022 | January 31, 2027 | NAIR-GILL, EVAN | reporter.nih.gov |
| Targeting ER stress response in B-cell chronic lymphocytic leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,620,598 | September 17, 2013 | March 31, 2030 | HU, CHIH-CHI ANDREW | reporter.nih.gov |
| Epigenetic Alterations and Targeted Therapies in North American ATLL | NIH | National Cancer Institute | 2023 to 2025 | $1,618,511 | April 1, 2023 | March 31, 2028 | YE, BIHUI HILDA | reporter.nih.gov |
| Dissecting the Role Ubiquitin E3 Ligase UBR5 in Lymphomagenesis | NIH | National Cancer Institute | 2022 to 2025 | $1,608,284 | August 1, 2021 | July 31, 2026 | BUCKLEY, SHANNON | reporter.nih.gov |
| Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,603,351 | September 15, 2022 | June 30, 2027 | DAVIDS, MATTHEW S | reporter.nih.gov |
| Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,600,482 | September 1, 2011 | June 30, 2027 | DITTMER, DIRK P | reporter.nih.gov |
| Role of KLHL6 inactivation in mature B-cell malignancies | NIH | National Cancer Institute | 2022 to 2025 | $1,596,563 | August 1, 2016 | November 30, 2026 | BUSINO, LUCA | reporter.nih.gov |
| THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS | NIH | National Cancer Institute | 2021 to 2025 | $1,578,483 | February 1, 2024 | January 31, 2026 | WILCOX, RYAN A | reporter.nih.gov |
| Defining mechanisms of gammaherpesvirus-driven genomic instability in B cells | NIH | National Cancer Institute | 2022 to 2025 | $1,567,623 | April 4, 2014 | February 28, 2027 | FORREST, JAMES CRAIG | reporter.nih.gov |
| Effects of EBV Type on Viral Reactivation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,565,574 | May 17, 2019 | April 30, 2025 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| HIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCL | NIH | National Cancer Institute | 2023 to 2025 | $1,563,766 | December 22, 2022 | November 30, 2027 | CRABTREE, GERALD R. | reporter.nih.gov |
| Epiproteomics of Sezary Syndrome | NIH | National Cancer Institute | 2022 to 2024 | $1,560,839 | June 1, 2020 | May 31, 2026 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Dysregulated mechanoimmunology of epigenetics-driven lymphomas | NIH | National Cancer Institute | 2023 to 2025 | $1,542,866 | May 9, 2023 | April 30, 2028 | SINGH, ANKUR | reporter.nih.gov |
| Transcriptional Control of Cellular Survival and Proliferation in KSHV-transformed B Cells | NIH | National Cancer Institute | 2021 to 2024 | $1,529,587 | April 13, 2020 | March 31, 2026 | GOTTWEIN, EVA HENRIETTE | reporter.nih.gov |
| Epigenetic Regulation of KSHV Genome Replication | NIH | National Cancer Institute | 2021 to 2023 | $1,505,469 | August 1, 2019 | July 31, 2025 | ROBERTSON, ERLE S. | reporter.nih.gov |
| Role of EBV Lytic Infection in Viral Tumorigenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,505,005 | July 1, 2019 | June 30, 2025 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| Targeting microRNAs in the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs | NIH | National Cancer Institute | 2021 to 2024 | $1,502,615 | February 15, 2020 | January 31, 2025 | SLACK, FRANK J. | reporter.nih.gov |
| Geospatially modeled environmental risk factors for lymphoid malignancies | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $1,500,831 | January 15, 2024 | October 31, 2028 | BIRMANN, BRENDA M | reporter.nih.gov |
| Mechanisms of enhancer regulation in leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,487,277 | January 1, 2019 | December 31, 2023 | AIFANTIS, IANNIS | reporter.nih.gov |
| Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response | NIH | National Cancer Institute | 2022 to 2025 | $1,485,537 | March 1, 2022 | February 28, 2027 | RINCON, MERCEDES | reporter.nih.gov |
| Mechanisms of STING in malignant progression and therapy of CLL. | NIH | National Cancer Institute | 2023 to 2025 | $1,451,820 | February 1, 2023 | January 31, 2028 | HU, CHIH-CHI ANDREW | reporter.nih.gov |
| Epigenetic Regulation of Epstein-Barr Virus | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $1,451,108 | January 15, 2022 | December 31, 2026 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Genetic Origins of Adverse Outcomes in African Americans with Lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,432,788 | April 18, 2023 | March 31, 2028 | DAVE, SANDEEP | reporter.nih.gov |
| Smoothened as a Novel Signal Stabilization Scaffold in Doxorubicin Resistance | NIH | National Cancer Institute | 2021 to 2023 | $1,431,130 | April 3, 2019 | March 31, 2025 | LANDGRAF, RALF | reporter.nih.gov |
| Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $1,423,030 | May 1, 2022 | April 30, 2027 | WIEMER, ANDREW J | reporter.nih.gov |
| Developing novel CAR T cell designs using combinatorial antigen detection | NIH | National Cancer Institute | 2021 to 2025 | $1,421,654 | April 1, 2021 | March 31, 2026 | ALLEN, GREG MANESS | reporter.nih.gov |
| Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation | NIH | National Cancer Institute | 2022 to 2025 | $1,418,567 | August 4, 2016 | March 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| B cell antigen receptor (BCR)-driven mechanistic connection between B cell lymphomagenesis and autoimmunity | NIH | National Cancer Institute | 2021 to 2024 | $1,415,931 | June 1, 2021 | May 31, 2025 | WANG, JING HONG | reporter.nih.gov |
| Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,415,907 | August 15, 2022 | June 30, 2027 | RATNER, LEE | reporter.nih.gov |
| Chemokines and Lymphoid Tissue Organization and Function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,409,982 | April 1, 1999 | August 31, 2024 | CYSTER, JASON G | reporter.nih.gov |
| Structure and Function of EBV Protein Complexes that Trigger Epithelial Cell Entry | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,408,573 | February 6, 2018 | January 31, 2024 | LONGNECKER, RICHARD M | reporter.nih.gov |
| Genetic pleiotropy across pediatric cancers, and cancer-related outcomes | NIH | National Cancer Institute | 2024 to 2025 | $1,395,864 | May 16, 2024 | April 30, 2029 | WANG, ZHAOMING | reporter.nih.gov |
| Notch and GATA-3 as novel therapeutic targets in T-cell lymphomas | NIH | National Cancer Institute | 2021 to 2024 | $1,395,284 | December 1, 2019 | November 30, 2024 | WILCOX, RYAN A | reporter.nih.gov |
| Identifying Functional Drivers of MYC Activation via Developmental Enhancers in Diffuse Large B-cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $1,388,419 | July 1, 2020 | June 30, 2025 | RYAN, RUSSELL JAMES HUBBARD | reporter.nih.gov |
| Developing newly combined therapeutic strategies for mature B cell lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,382,659 | April 1, 2021 | March 31, 2024 | WANG, JING HONG | reporter.nih.gov |
| Targeting EGR1 signaling pathways in diffuse large B cell lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,373,977 | December 20, 2021 | November 30, 2026 | RUI, LIXIN | reporter.nih.gov |
| Drug-Free Macromolecular Therapeutics | NIH | National Cancer Institute | 2021 to 2024 | $1,370,957 | July 1, 2011 | November 30, 2025 | KOPECEK, JINDRICH H. | reporter.nih.gov |
| Impact of Targeted Therapy on Cancer-Related Cognitive Impairment | NIH | National Cancer Institute | 2024 to 2025 | $1,364,661 | September 1, 2024 | August 31, 2029 | GONZALEZ, BRIAN D | reporter.nih.gov |
| Roles of LMP1 and MYC in EBV-induced B-cell tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,353,918 | September 1, 2023 | August 31, 2028 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| Targeting delivery of mAbs to CNS metastases | NIH | National Cancer Institute | 2021 to 2024 | $1,345,194 | August 1, 2020 | April 30, 2026 | WEN, JING | reporter.nih.gov |
| A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $1,330,000 | August 1, 2024 | July 31, 2027 | VERA, JUAN FERNANDO | reporter.nih.gov |
| Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,326,660 | August 1, 2019 | June 30, 2023 | VAN DEN BRINK, MARCEL R M | reporter.nih.gov |
| Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,326,247 | August 5, 2023 | April 30, 2028 | ADDISON, DANIEL | reporter.nih.gov |
| Rational Vaccine Design to prevent HIV-Associated Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $1,312,191 | February 1, 2024 | January 31, 2029 | MCGUIRE, ANDREW | reporter.nih.gov |
| Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,310,217 | July 1, 2023 | October 30, 2025 | WANG, LILI | reporter.nih.gov |
| Genetic Analysis of Myeloproliferative Disease | NIH | National Cancer Institute | 2021 to 2024 | $1,293,659 | April 1, 1999 | February 28, 2026 | COWELL, JOHN K | reporter.nih.gov |
| Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,292,812 | July 15, 2023 | June 30, 2028 | SWAMINATHAN, SRIVIDYA | reporter.nih.gov |
| Targeting EBV-associated lymphomas | NIH | National Cancer Institute | 2024 to 2025 | $1,290,024 | September 10, 2024 | August 31, 2029 | DAMANIA, BLOSSOM A | reporter.nih.gov |
| Identifying Multi-Level Predictors and Outcomes of Oral Anticancer Medication Adherence Initiation and Persistence among Patients with Hematologic Malignancies | NIH | National Cancer Institute | 2024 to 2025 | $1,283,191 | August 1, 2024 | July 31, 2029 | BELCHER, SARAH M. | reporter.nih.gov |
| Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomas | NIH | National Cancer Institute | 2024 to 2025 | $1,277,693 | January 1, 2024 | December 31, 2028 | WILCOX, RYAN A | reporter.nih.gov |
| CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,275,832 | August 1, 2021 | March 1, 2024 | WANG, ZHIRUI | reporter.nih.gov |
| Replication stress in hematopoiesis and lymphomagenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,266,867 | December 1, 2018 | November 30, 2025 | EISCHEN, CHRISTINE M. | reporter.nih.gov |
| NanoOptogenetic immunotherapy for B cell lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,264,108 | May 1, 2019 | April 30, 2025 | HAN, GANG | reporter.nih.gov |
| Comprehensive Molecular and Clinical Characterization of Acute and Chronic Neurotoxicity Following CAR-T Cell Therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,262,391 | September 15, 2024 | August 31, 2029 | SANTOMASSO, BIANCA DENISE | reporter.nih.gov |
| PET/CT Imaging of Venous Thromboembolism in Pediatric, Adolescent, and Young Adult Oncology | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,254,556 | July 15, 2024 | May 31, 2029 | STACY, MITCHEL R | reporter.nih.gov |
| Targeting Wnt signaling pathway | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,251,430 | April 1, 2023 | March 31, 2027 | CAI, JIANFENG | reporter.nih.gov |
| Stringent Latent Epstein-Barr Virus (EBV) Infection Collaborates with Cellular Gene Alterations to Induce EBV+ Lymphomas | NIH | National Cancer Institute | 2023 to 2025 | $1,247,765 | July 1, 2023 | June 30, 2028 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| A Next-Generation Nucleoside Prodrug for Diffuse Large B-Cell Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $1,247,192 | December 18, 2023 | November 30, 2028 | POMERANTZ, RICHARD T | reporter.nih.gov |
| The role of ATM in the suppression of lymphoid malignancy | NIH | National Cancer Institute | 2021 to 2025 | $1,239,512 | March 1, 2011 | July 31, 2029 | ZHA, SHAN | reporter.nih.gov |
| Novel enhancement of antibody therapy through NOD2 activation | NIH | National Cancer Institute | 2024 to 2025 | $1,236,215 | September 1, 2024 | August 31, 2029 | TRIDANDAPANI, SUSHEELA | reporter.nih.gov |
| Clinical and Genetic Origins of Monomorphic Epitheliotropic Intestinal T Cell Lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,228,976 | January 1, 2023 | December 31, 2027 | DAVE, SANDEEP | reporter.nih.gov |
| USP7 targeting by HHV-8 vIRFs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,228,125 | March 1, 2019 | February 28, 2025 | NICHOLAS, JOHN | reporter.nih.gov |
| Characterization of Diverse Pediatric Cancers in LMIC Using Low-Cost Nanopore Sequencing | NIH | National Cancer Institute | 2024 to 2025 | $1,226,342 | July 15, 2024 | June 30, 2026 | WANG, JEREMY R | reporter.nih.gov |
| Methods and Tools for Integrating Pathomics Data into Cancer Registries | NIH | National Cancer Institute | 2021 to 2022 | $1,223,841 | April 1, 2018 | March 31, 2024 | SALTZ, JOEL H. | reporter.nih.gov |
| Characterizing stem cell-like B cell subpopulations and dissecting their role in tumorigenesis | NIH | National Cancer Institute | 2023 to 2025 | $1,207,701 | July 1, 2023 | June 30, 2028 | APOSTOLOU, EFFIE | reporter.nih.gov |
| Restriction of KSHV by cellular RNA decay pathways | NIH | National Cancer Institute | 2023 to 2025 | $1,200,939 | April 1, 2023 | March 31, 2028 | KARIJOLICH, JOHN | reporter.nih.gov |
| Developing novel therapy to improve outcomes in MCL | NIH | National Cancer Institute | 2023 to 2025 | $1,200,590 | July 12, 2023 | June 30, 2028 | SEHGAL, LALIT | reporter.nih.gov |
| PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $1,199,248 | August 2, 2017 | July 31, 2023 | LIN, YI | reporter.nih.gov |
| Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,194,123 | May 1, 2024 | April 30, 2029 | LU, YONG | reporter.nih.gov |
| R-loop-induced DNA damage during immunoglobulin class switch recombination | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,174,235 | August 5, 2019 | July 31, 2025 | BARLOW, JACQUELINE | reporter.nih.gov |
| Functional genetics of human innate immunity in the bimodal gamma delta T cell response to Epstein-Barr Virus and in education of NK cells and their re-education to respond to autologous cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,173,750 | February 5, 2019 | July 31, 2024 | PARHAM, PETER R | reporter.nih.gov |
| Modeling cancer risk and environmental and socio-spatial exposures using residential histories | NIH | National Cancer Institute | 2021 to 2024 | $1,173,164 | April 1, 2021 | March 31, 2026 | SABO, ROY TRAVIS | reporter.nih.gov |
| Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH) | NIH | National Cancer Institute | 2023 to 2024 | $1,169,589 | September 1, 2023 | October 1, 2024 | DHARNIDHARKA, VIKAS R. | reporter.nih.gov |
| Direct chemical control of the hematopoietic master transcription factor PU.1 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,169,375 | January 1, 2021 | December 31, 2025 | POON, GREGORY MAN KAI | reporter.nih.gov |
| The Role of Follicular CD8+ T Cells in Pathogenesis of AIDS-NHL. | NIH | National Cancer Institute | 2021 to 2023 | $1,168,002 | August 9, 2019 | July 31, 2025 | EPELDEGUI, MARTA | reporter.nih.gov |
| Role of E3 Ligase UBR5 in Alternative Splicing during B Cell Development and Activation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,158,775 | August 25, 2021 | July 31, 2025 | BUCKLEY, SHANNON | reporter.nih.gov |
| A Single-Cell Proteomic instrument for Predictive Product Quality Check in Autologous CAR-T Immunotherapies | NIH | National Cancer Institute | 2021 | $1,150,207 | September 21, 2016 | May 31, 2022 | ZHOU, JING | reporter.nih.gov |
| Multimodal Learning for Contextually-Aware Longitudinal PET/CT image analysis | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $1,141,556 | December 1, 2023 | November 30, 2027 | BRADSHAW, TYLER J | reporter.nih.gov |
| Targeting IKKepsilon-mediated nucleotide synthesis in KSHV-associated lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,138,031 | July 1, 2023 | June 30, 2028 | FENG, PINGHUI | reporter.nih.gov |
| Mapping the blood cancer exposome for environmental risk profiles of mature B-cell neoplasms | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $1,136,355 | February 25, 2022 | November 30, 2027 | WALKER, DOUGLAS IAN | reporter.nih.gov |
| Ultra-fast manufactured CAR-T therapy | NIH | National Cancer Institute | 2025 | $1,125,000 | September 15, 2025 | August 31, 2027 | WALD, DAVID | reporter.nih.gov |
| A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma | NIH | National Cancer Institute | 2025 | $1,124,607 | July 1, 2025 | June 30, 2027 | HEIN, SARAH MARIE | reporter.nih.gov |
| CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,124,168 | August 1, 2021 | January 31, 2027 | WANG, ZHIRUI | reporter.nih.gov |
| Elucidating the mechanism and consequences of aberrant cyclin D1 gene expression | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,113,492 | August 1, 2020 | July 31, 2025 | MASAMHA, CHIONISO PATIENCE | reporter.nih.gov |
| (PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $1,104,883 | September 1, 2018 | February 29, 2024 | DANIAL, NIKA N | reporter.nih.gov |
| Molecular modulators of radiation-induced chromosome instability and hematopoietic damage | NIH | National Cancer Institute | 2023 to 2025 | $1,099,626 | May 1, 2015 | June 30, 2027 | SHEN, ZHIYUAN | reporter.nih.gov |
| DNA-PKcs and PIDD interaction in DNA damage response | NIH | National Cancer Institute | 2021 to 2023 | $1,096,903 | September 1, 2019 | August 31, 2025 | DAVIS, ANTHONY J | reporter.nih.gov |
| Remodeling of the host epigenome during EBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,096,596 | June 7, 2024 | April 30, 2029 | TEMPERA, ITALO | reporter.nih.gov |
| Investigating Mechanisms of Deregulated Nucleotide Metabolism in Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,094,089 | August 1, 2019 | July 31, 2024 | CUNNINGHAM, TOM | reporter.nih.gov |
| Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure. | NIH | National Cancer Institute | 2023 to 2025 | $1,093,197 | April 1, 2023 | March 31, 2028 | DAHER, MAY | reporter.nih.gov |
| Genetic and Epigenetic Biomarkers for B-cell Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,090,132 | January 1, 2020 | June 30, 2025 | YOUNG, KEN H. | reporter.nih.gov |
| Innovations in diagnosis for lymphadenopathy across HIV Centers of Excellence in Malawi | NIH | National Cancer Institute | 2024 to 2025 | $1,088,500 | July 1, 2024 | June 30, 2029 | PAINSCHAB, MATTHEW SCOTT | reporter.nih.gov |
| Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $1,086,087 | July 2, 2019 | January 29, 2023 | CONEJO-GARCIA, JOSE R | reporter.nih.gov |
| RPMS1 circular RNAs in EBV malignancies | NIH | National Cancer Institute | 2021 to 2023 | $1,083,260 | June 1, 2019 | May 31, 2024 | FLEMINGTON, ERIK K | reporter.nih.gov |
| Integrative approach to identify genomic features that shape the immune landscape and predict immunotherapy response in diffuse large B cell lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,083,199 | May 1, 2023 | April 30, 2028 | KLINE, JUSTIN PAUL | reporter.nih.gov |
| Nano-Therapeutic Approaches for Oncogenic Herpesvirus-Mediated Malignancies | NIH | National Cancer Institute | 2021 to 2022 | $1,074,790 | July 6, 2018 | June 30, 2024 | IZUMIYA, YOSHIHIRO | reporter.nih.gov |
| Improving Exercise Capacity with a Tailored Physical Activity Intervention in Lymphoma Patients Undergoing Treatment | NIH | National Cancer Institute | 2022 to 2024 | $1,074,697 | December 1, 2018 | August 31, 2025 | HUNDLEY, WILLIAM GREGORY | reporter.nih.gov |
| Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL | NIH | National Cancer Institute | 2024 to 2025 | $1,066,133 | April 1, 2024 | March 31, 2029 | HESS, BRIAN | reporter.nih.gov |
| KSHV interactions with host nuclear innate response components | NIH | National Cancer Institute | 2021 to 2023 | $1,065,189 | April 8, 2019 | January 31, 2025 | CHANDRAN, BALA | reporter.nih.gov |
| Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCL | NIH | National Cancer Institute | 2021 to 2023 | $1,064,045 | April 1, 2019 | March 31, 2025 | LOSSOS, IZIDORE S | reporter.nih.gov |
| The Role of IL-15 in Cutaneous T-cell Lymphoma Progression | NIH | National Cancer Institute | 2023 to 2025 | $1,052,708 | July 20, 2023 | June 30, 2028 | MISHRA, ANJALI | reporter.nih.gov |
| Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,047,558 | August 8, 2011 | June 30, 2031 | PIDALA, JOSEPH A | reporter.nih.gov |
| Role of FBXO45 in Diffuse Large B Cell Lymphoma Pathogenesis | NIH | National Cancer Institute | 2022 to 2023 | $1,041,861 | October 1, 2022 | June 30, 2024 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Epstein-Barr Virus Driven Tonsillar Versus Peripheral B-cell One-Carbon Metabolic Network Remodeling | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,036,702 | May 6, 2024 | April 30, 2029 | GEWURZ, BENJAMIN ELISON | reporter.nih.gov |
| Genomic biomarkers of splenic lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $1,036,096 | December 4, 2020 | July 31, 2022 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Mechanisms of treatment failure in chimeric antigen receptor T cell therapy | NIH | National Cancer Institute | 2021 | $1,032,791 | February 1, 2019 | March 31, 2022 | TILL, BRIAN | reporter.nih.gov |
| Adapting flow cytometry methods for early detection of acute hematologic malignancies in Kenya including the improvement of sample flow processes and technical training of personnel | NIH | National Cancer Institute | 2024 to 2025 | $1,030,249 | July 2, 2024 | June 30, 2029 | VIK, TERRY A | reporter.nih.gov |
| Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells | NIH | National Cancer Institute | 2024 to 2025 | $1,027,718 | August 1, 2024 | July 31, 2029 | SMITH, ERIC L | reporter.nih.gov |
| Validation of Duoseq as a Genomic Swiss Army Knife for the Diagnosis of Lymphomas | NIH | National Cancer Institute | 2025 | $1,022,841 | January 1, 2025 | August 31, 2027 | HAPP, LANIE ELIZABETH | reporter.nih.gov |
| BMT Core- The Ohio State University blood and marrow transplant research consortium | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,022,473 | August 8, 2011 | June 30, 2031 | VASU, SUMITHIRA | reporter.nih.gov |
| BMT Core- Medical College of Wisconsin | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,022,400 | July 27, 2017 | June 30, 2031 | SHAH, NIRAV | reporter.nih.gov |
| Targeting High-Risk Lymphoid Neoplasms | NIH | National Cancer Institute | 2021 | $1,021,025 | August 1, 2019 | June 30, 2022 | WEINSTOCK, DAVID MARC | reporter.nih.gov |
| Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies | NIH | National Cancer Institute | 2021 | $1,004,844 | September 1, 2017 | July 31, 2023 | DRUKER, BRIAN J | reporter.nih.gov |
| Human T Cell Lymphotropic Virus Vaccine Development | NIH | National Cancer Institute | 2024 | $999,969 | February 1, 2022 | August 31, 2026 | BARBER, GLEN N | reporter.nih.gov |
| Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy | NIH | National Cancer Institute | 2025 | $992,425 | September 8, 2025 | August 31, 2027 | DEISHER, THERESA A | reporter.nih.gov |
| Cell-targeted glutamine antagonists as a novel therapy for lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $982,421 | July 2, 2018 | June 30, 2024 | SLUSHER, BARBARA STAUCH | reporter.nih.gov |
| Mechanisms of treatment failure in chimeric antigen receptor T cell therapy | NIH | National Cancer Institute | 2022 to 2023 | $979,067 | February 1, 2019 | July 31, 2025 | TILL, BRIAN | reporter.nih.gov |
| Circulating biomarkers of ALK+ anaplastic large cell lymphoma | NIH | National Cancer Institute | 2022 to 2024 | $974,438 | October 1, 2022 | July 31, 2025 | LIM, MEGAN S. | reporter.nih.gov |
| Targeted Therapy for Leukemia | NIH | National Cancer Institute | 2021 | $971,232 | September 1, 2015 | April 30, 2023 | BYRD, JOHN C. | reporter.nih.gov |
| Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell Therapies | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $963,456 | August 8, 2011 | June 30, 2031 | PUSIC, ISKRA | reporter.nih.gov |
| WASp signaling in T-cell lymphomas | NIH | National Cancer Institute | 2024 to 2025 | $959,507 | July 15, 2024 | June 30, 2026 | MURGA-ZAMALLOA, CARLOS A. | reporter.nih.gov |
| Dissecting mechanisms of resistance underlying CD47-SIRPα inhibition in T-cell lymphomas | NIH | National Cancer Institute | 2022 to 2024 | $940,447 | July 1, 2020 | June 30, 2025 | JAIN, SALVIA | reporter.nih.gov |
| Mapping and targeting 3D regulatory elements in leukemia and lymphoma-Supplement | NIH | National Cancer Institute | 2025 | $935,081 | December 13, 2024 | November 30, 2029 | AIFANTIS, IANNIS | reporter.nih.gov |
| Efforts to Discover Novel Therapies and Reduce Treatment Toxicities for Lymphoma and Chronic Lymphocytic Leukemia Patients Through Collaboration and the NCTN | NIH | National Cancer Institute | 2025 | $935,075 | September 12, 2025 | August 31, 2029 | HU, BOYU | reporter.nih.gov |
| Elucidating the molecular mechanism of Daple- FLT3 and Daple-PDGFRB gene fusion in blood cancers | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $933,867 | July 15, 2022 | June 30, 2026 | EAR, JASON | reporter.nih.gov |
| Defining Epidrivers of CLL Evolution in Response to Targeted Therapy | NIH | National Cancer Institute | 2021 to 2022 | $923,482 | September 19, 2018 | August 31, 2024 | LANDAU, DAN | reporter.nih.gov |
| Nanodelivery platform for antibody drugs targeting NHL | NIH | National Cancer Institute | 2021 to 2022 | $916,741 | July 18, 2018 | June 30, 2024 | KAMATA, MASAKAZU | reporter.nih.gov |
| Targeting the Notch:Myc axis in leukemia/lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $908,222 | January 1, 2018 | December 31, 2023 | PEAR, WARREN S | reporter.nih.gov |
| Therapeutic Inhibition of MYC:TRRAP Interaction in Cancer | NIH | National Cancer Institute | 2025 | $906,627 | June 18, 2024 | May 31, 2027 | FERIS, ED | reporter.nih.gov |
| Genomic biomarkers for cutaneous T-cell Lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $896,965 | February 15, 2020 | July 31, 2022 | LIM, MEGAN S. | reporter.nih.gov |
| Metabolic Network Remodeling in Epstein-Barr Virus Lymphomagenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $895,000 | March 15, 2018 | February 28, 2023 | GEWURZ, BENJAMIN ELISON | reporter.nih.gov |
| NCI Research Specialist (Clinician Scientist) Award | NIH | National Cancer Institute | 2025 | $882,470 | September 1, 2025 | August 31, 2030 | SCHAFER, ERIC STEPHEN | reporter.nih.gov |
| KSHV Infection And Persistence | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $877,104 | April 10, 2025 | March 31, 2030 | KAYE, KENNETH M | reporter.nih.gov |
| Therapy for Non-Hodgkin lympoma | NIH | National Cancer Institute | 2024 to 2025 | $871,436 | September 1, 2024 | August 31, 2029 | DAMANIA, BLOSSOM A | reporter.nih.gov |
| CDK6-dependent metabolic reprogramming in KSHV pathogenesis | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $870,741 | September 1, 2024 | May 31, 2029 | ZHAO, JUN | reporter.nih.gov |
| Mechanisms of Obesity-Induced Genetic Instability at Endogenous Mutation Hotspots | NIH | National Cancer Institute | 2021 to 2022 | $862,898 | January 1, 2018 | December 31, 2023 | VASQUEZ, KAREN M | reporter.nih.gov |
| Genomic biomarkers for cutaneous T-cell Lymphoma | NIH | National Cancer Institute | 2022 to 2024 | $861,358 | October 1, 2022 | January 31, 2026 | LIM, MEGAN S. | reporter.nih.gov |
| Predictive markers for personalized therapy in chronic lymphocytic leukemia | NIH | National Cancer Institute | 2023 to 2025 | $857,793 | April 1, 2023 | March 31, 2028 | SOUMERAI, JACOB | reporter.nih.gov |
| Radioimmunotherapy Combinations for B-cell Malignancy | NIH | National Cancer Institute | 2022 to 2024 | $855,237 | January 1, 1998 | February 29, 2024 | GREEN, DAMIAN J. | reporter.nih.gov |
| Characterization of short H2A Oncohistones in Cancer | NIH | National Cancer Institute | 2022 to 2025 | $846,776 | September 1, 2022 | August 31, 2027 | SARTHY, JAY | reporter.nih.gov |
| Cell decision underlying B-cell immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $845,915 | February 1, 2018 | January 31, 2025 | HOFFMANN, ALEXANDER | reporter.nih.gov |
| Cancer Gene Discovery to Identify Targetable Targets | NIH | National Cancer Institute | 2021 | $843,904 | September 11, 2015 | August 31, 2022 | CROCE, CARLO M | reporter.nih.gov |
| Define the Role of POT1 Mutation in Genome Instability and Cancer | NIH | National Cancer Institute | 2021 to 2022 | $842,937 | April 1, 2021 | August 31, 2024 | SFEIR, AGNEL | reporter.nih.gov |
| Investigating immunophenotype and metabolism of TCR KO donor and third-party CD19-targeted chimeric antigen receptor T cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $835,380 | September 25, 2021 | August 31, 2026 | SMITH, MELODY | reporter.nih.gov |
| A multimodal approach for precision immuno-oncology in lymphoma treated with CAR-T cells | NIH | National Cancer Institute | 2023 to 2025 | $833,055 | August 7, 2023 | July 31, 2028 | SHOUVAL, RONI | reporter.nih.gov |
| Mutant p53 gain-of-function as an actionable target in cancer therapy | NIH | National Cancer Institute | 2021 to 2024 | $828,596 | September 11, 2020 | August 31, 2025 | NEMAJEROVA, ALICE | reporter.nih.gov |
| A randomized trial of cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma and pre-existing cardiomyopathy or prior anthracycline exposure | NIH | National Cancer Institute | 2025 | $818,625 | September 1, 2025 | August 31, 2030 | UPSHAW, JENICA | reporter.nih.gov |
| Thriving Beyond Treatment: A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship | NIH | National Cancer Institute | 2025 | $817,829 | September 12, 2025 | August 31, 2030 | PEREZ-LOUGEE, GISELLE KATIRIA | reporter.nih.gov |
| COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children | NIH | National Cancer Institute | 2021 | $800,000 | April 18, 2019 | February 28, 2022 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Novel mechanisms of B cell tumorigenesis and relapse | NIH | National Cancer Institute | 2024 to 2025 | $781,862 | June 1, 2024 | May 31, 2029 | XIE, PING | reporter.nih.gov |
| Integrated delivery of cancer control interventions for adolescents and young adults living with HIV in Zambia | NIH | National Cancer Institute | 2022 | $779,696 | September 2, 2022 | August 31, 2023 | SUBRAMANIAN, SUJHA | reporter.nih.gov |
| Impact of HIV on the Tumor Microenvironment | NIH | National Cancer Institute | 2021 to 2022 | $774,384 | June 1, 2018 | May 31, 2024 | DITTMER, DIRK P | reporter.nih.gov |
| Role of KSHV Viral Proteins in Signaling and Pathogenesis | NIH | National Cancer Institute | 2021 to 2022 | $774,364 | July 15, 2002 | July 31, 2024 | DAMANIA, BLOSSOM A | reporter.nih.gov |
| Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $773,360 | February 20, 2012 | April 30, 2024 | HIEBERT, SCOTT W | reporter.nih.gov |
| Epiproteomics of Sezary Syndrome | NIH | National Cancer Institute | 2021 to 2022 | $769,004 | June 1, 2020 | January 31, 2023 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| PET imaging of Chemotherapy-Induced Cardiotoxicity | NIH | National Heart, Lung, and Blood Institute | 2025 | $768,567 | September 15, 2025 | August 31, 2029 | SHARMA, VIJAY | reporter.nih.gov |
| Prognostic and Therapeutic Implications of IFNAR1 Signaling on CAR T Cell Therapy for Cancer | NIH | National Cancer Institute | 2021 to 2025 | $768,255 | July 1, 2021 | June 30, 2026 | ATHERTON, MATTHEW JOHN | reporter.nih.gov |
| Role of FOXO1 mutations in the pathogenesis of B cell non-Hodgkin lymphomas | NIH | National Cancer Institute | 2021 to 2022 | $763,154 | February 5, 2018 | January 31, 2024 | DOMINGUEZ-SOLA, DAVID | reporter.nih.gov |
| Viral and host strategies for regulation of KSHV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $762,500 | June 1, 2018 | May 31, 2024 | TOTH, ZSOLT | reporter.nih.gov |
| Role of KMT2D Gene Inactivation in B cell Non Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $761,805 | January 1, 2013 | June 30, 2024 | PASQUALUCCI, LAURA | reporter.nih.gov |
| Tracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining Transformation | NIH | National Cancer Institute | 2022 to 2025 | $756,000 | September 1, 2022 | August 31, 2027 | PARRY, ERIN M | reporter.nih.gov |
| EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized Mice | NIH | National Cancer Institute | 2021 to 2022 | $755,384 | June 13, 2018 | August 31, 2023 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| Regulation of EBV Latency by EBNA1 | NIH | National Cancer Institute | 2021 to 2022 | $754,187 | August 1, 2002 | June 30, 2023 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Exploiting tumor metabolism to optimize T cell therapy | NIH | National Cancer Institute | 2021 to 2025 | $753,194 | September 5, 2018 | August 31, 2029 | SERGANOVA, INNA | reporter.nih.gov |
| Integrative Prediction of Therapeutic Response in T-cell Lymphoma by Omic and Spatial Modeling | NIH | National Cancer Institute | 2023 to 2025 | $747,000 | March 1, 2021 | February 28, 2026 | NIRMAL, AJIT JOHNSON | reporter.nih.gov |
| Exploiting Metabolism to Uncloak Epstein-Barr Virus Immunogens in Latently Infected B-cells | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $746,613 | July 15, 2023 | July 14, 2026 | GUO, RUI | reporter.nih.gov |
| Epstein-Barr Virus nuclear antigen leader protein in transcription regulation | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $744,716 | June 1, 2023 | May 31, 2027 | WANG, CHONG | reporter.nih.gov |
| New mechanisms for modulating the MALT1 oncoprotein | NIH | National Cancer Institute | 2021 to 2022 | $744,697 | February 13, 2018 | January 31, 2024 | MCALLISTER-LUCAS, LINDA M | reporter.nih.gov |
| Molecular modulators of radiation-induced chromosome instability and hematopoietic damage | NIH | National Cancer Institute | 2021 to 2022 | $743,092 | May 1, 2015 | June 30, 2023 | SHEN, ZHIYUAN | reporter.nih.gov |
| Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $741,150 | September 21, 2018 | August 31, 2023 | AMENGUAL, JENNIFER E. | reporter.nih.gov |
| CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHL | NIH | National Cancer Institute | 2025 | $738,698 | December 1, 2024 | November 30, 2029 | WANG, XIULI | reporter.nih.gov |
| Control Mechanisms of Human Voltage Gated Proton Channels, hHv1 | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $737,900 | May 1, 2018 | January 31, 2024 | DECOURSEY, THOMAS E | reporter.nih.gov |
| Self-assembled multifunctional aptamer-complex biomaterial for precision medicine | NIH | National Cancer Institute | 2021 to 2022 | $731,474 | January 15, 2018 | June 30, 2024 | ZU, YOULI | reporter.nih.gov |
| Tumor suppressive functions of TET proteins in B cell malignancies: role of G-quadruplex structures | NIH | National Cancer Institute | 2022 to 2024 | $725,959 | March 10, 2020 | February 28, 2025 | SHUKLA, VIPUL | reporter.nih.gov |
| Attacking the Tumor Cell-Immune Milieu Interface to Overcome Richter's Transformation | NIH | National Cancer Institute | 2025 | $721,723 | December 16, 2024 | November 30, 2029 | WANG, LILI | reporter.nih.gov |
| Spatiotemporal Gene Regulation and KSHV Replication | NIH | National Cancer Institute | 2021 to 2022 | $718,276 | July 1, 2018 | June 30, 2023 | IZUMIYA, YOSHIHIRO | reporter.nih.gov |
| Mechanisms regulating chimeric antigen receptor T-cell activity in cancer | NIH | National Cancer Institute | 2021 to 2023 | $714,405 | August 1, 2019 | July 31, 2025 | SINGH, NATHAN | reporter.nih.gov |
| Translating Insights in Follicular Lymphoma for Improved Diagnosis and Classification | NIH | National Cancer Institute | 2025 | $714,110 | September 1, 2025 | August 31, 2030 | PARK, CHRISTOPHER Y | reporter.nih.gov |
| The Role of H3.3 histone variant in the pathogenesis of oral Kaposi's Sarcoma | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $710,990 | September 4, 2018 | June 30, 2024 | RENNE, ROLF F | reporter.nih.gov |
| The role of inflammation in driving leukemogenesis in germline predisposition syndromes | NIH | National Cancer Institute | 2022 | $707,850 | May 1, 2022 | April 30, 2023 | GODLEY, LUCY ANN | reporter.nih.gov |
| Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity | NIH | National Heart, Lung, and Blood Institute | 2025 | $703,582 | August 5, 2023 | April 30, 2028 | ADDISON, DANIEL | reporter.nih.gov |
| Targeting Tumor-Associated Macrophages to Treat Lymphoma | NIH | National Cancer Institute | 2025 | $702,495 | August 1, 2025 | July 31, 2030 | HUANG, WENDONG | reporter.nih.gov |
| Understanding mechanisms of BTK inhibitor and degrader resistance in patients with chronic lymphocytic leukemia | NIH | National Cancer Institute | 2024 to 2025 | $702,262 | July 1, 2024 | June 30, 2029 | TAYLOR, JUSTIN | reporter.nih.gov |
| Defining the Biological and Mechanistic Implications of XPO1 Mutations in Hematologic Malignancies | NIH | National Cancer Institute | 2021 to 2023 | $702,046 | August 1, 2018 | January 31, 2024 | TAYLOR, JUSTIN | reporter.nih.gov |
| Enhancing the efficacy of immunotherapy in DLBCL using rational combination approaches | NIH | National Cancer Institute | 2021 | $696,529 | September 30, 2017 | August 31, 2023 | LONDON, CHERYL A | reporter.nih.gov |
| ASB13 Control of EBV Life Cycle in B Cell and Epithelial Cell Cancers | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $691,788 | July 25, 2025 | June 30, 2030 | LI, RENFENG | reporter.nih.gov |
| Modeling and analysis of curative combination therapy for Diffuse Large B-Cell Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $689,162 | February 1, 2024 | January 31, 2029 | PALMER, ADAM CHRISTOPHER | reporter.nih.gov |
| Blood Brain Barrier Disruption during Chimeric Antigen Receptor (CAR) T cell therapy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $688,500 | September 1, 2020 | August 31, 2025 | GUST, JULIANE | reporter.nih.gov |
| Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $688,168 | April 1, 2024 | March 31, 2029 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| Radioimmunotherapy Combinations for B-cell Malignancy | NIH | National Cancer Institute | 2024 to 2025 | $688,017 | January 1, 1998 | July 31, 2026 | GREEN, DAMIAN J. | reporter.nih.gov |
| Aberrant V(D)J recombination in B cells initiates lymphoid malignancy | NIH | National Cancer Institute | 2024 to 2025 | $685,322 | February 15, 2024 | January 31, 2029 | PANNUNZIO, NICHOLAS | reporter.nih.gov |
| Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture | NIH | National Cancer Institute | 2024 to 2025 | $685,239 | July 7, 2021 | February 28, 2027 | KREBS, SIMONE | reporter.nih.gov |
| Mutant p53 as actionable cancer-specific target | NIH | National Cancer Institute | 2021 to 2022 | $681,979 | April 1, 2013 | May 31, 2025 | MOLL, UTE MARTHA | reporter.nih.gov |
| Nuclear Accumulation of D-type Cyclins and Oncogenesis | NIH | National Cancer Institute | 2021 to 2022 | $681,393 | July 1, 2001 | May 31, 2024 | DIEHL, JOHN ALAN | reporter.nih.gov |
| Lymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR Therapies | NIH | National Cancer Institute | 2021 to 2024 | $675,912 | March 9, 2020 | February 28, 2025 | FRANK, MATTHEW J. | reporter.nih.gov |
| Epigenetic Targeting of Afro-Caribbean Variant of HTLV-1 Related Adult T-cell Leukemia-lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $675,447 | January 1, 2018 | December 31, 2024 | RAMOS, JUAN CARLOS | reporter.nih.gov |
| Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome Modulation | NIH | National Cancer Institute | 2025 | $667,533 | January 1, 2025 | December 31, 2029 | FACCIABENE, ANDREA | reporter.nih.gov |
| Early Detection and Mechanisms of Cancer Immunotherapy Associated Cardiotoxicity | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $662,688 | August 15, 2021 | July 31, 2026 | ADDISON, DANIEL | reporter.nih.gov |
| Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study | NIH | National Cancer Institute | 2021 | $662,560 | January 1, 2020 | March 31, 2022 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| Improving shared decision-making around the use of disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $661,334 | July 1, 2022 | June 30, 2027 | SINGH, NAMRATA | reporter.nih.gov |
| Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell Lymphoma | NIH | National Cancer Institute | 2021 | $657,422 | August 1, 2017 | January 31, 2023 | NOVAK, ANNE JOSEPHINE | reporter.nih.gov |
| Aging-Related Biomarkers of Neurocognitive Function in Long-term Hodgkin Lymphoma Survivors | NIH | National Cancer Institute | 2022 to 2024 | $655,112 | January 3, 2021 | June 30, 2026 | WILLIAMS, ANNALYNN | reporter.nih.gov |
| Mapping the blood cancer exposome for environmental risk profiles of mature B-cell neoplasms | NIH | National Institute of Environmental Health Sciences | 2022 | $653,364 | February 25, 2022 | November 30, 2022 | WALKER, DOUGLAS IAN | reporter.nih.gov |
| Cell-Based HTS Campaign to Identify Negative Allosteric Modulators of the Leukemia-associated Tyrosine Kinase, BTK”. | NIH | National Cancer Institute | 2025 | $652,558 | January 1, 2025 | December 31, 2027 | JOHNSTON, PAUL A. | reporter.nih.gov |
| Determining Optimal Immunosuppression and Kidney Allocation Strategies for Mitigating Risks from Epstein-Barr Virus in Kidney Transplant Centers | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $644,770 | May 7, 2025 | April 30, 2030 | POTLURI, VISHNU SAGAR | reporter.nih.gov |
| Precision next-generation radioimmunotherapies to Cure Non-Hodgkin Lymphoma | NIH | National Cancer Institute | 2025 | $641,534 | December 5, 2024 | November 30, 2029 | WAHL, RICHARD LEO | reporter.nih.gov |
| Development of A HTLV-1 Vaccine | NIH | National Cancer Institute | 2025 | $601,378 | March 3, 2021 | June 30, 2027 | BARBER, GLEN N | reporter.nih.gov |
| Understanding viral mechanisms to inform oncolytic therapies for EBV-associated lymphomas in PLWH | NIH | National Institute of Dental & Craniofacial Research | 2025 | $601,309 | July 1, 2025 | March 31, 2030 | BHADURI-MCINTOSH, SUMITA | reporter.nih.gov |
| A Practical Approach to Tumor-Specific Aptamers for B-Cell Hematologic Malignancies | NIH | National Cancer Institute | 2022 to 2024 | $599,461 | May 1, 2022 | April 30, 2026 | LIN, QIAO | reporter.nih.gov |
| Vitamin D and Follicular Lymphoma | NIH | National Cancer Institute | 2022 | $592,475 | August 1, 2017 | July 31, 2024 | FRIEDBERG, JONATHAN W | reporter.nih.gov |
| Prevention of Anthracycline Chemotherapy Cardiotoxicity | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $592,200 | April 15, 2020 | January 1, 2025 | UPSHAW, JENICA | reporter.nih.gov |
| Human T cell Lymphotropic Virus Vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $588,155 | February 1, 2022 | June 30, 2024 | BARBER, GLEN N | reporter.nih.gov |
| Defining the epigenetic landscape and therapeutic vulnerabilities of Richter's syndrome in CRISPR-based mouse models | NIH | National Cancer Institute | 2023 to 2025 | $588,060 | May 19, 2023 | April 30, 2026 | TEN HACKEN, ELISA | reporter.nih.gov |
| Epigenetic Regulation of KSHV Latency | NIH | National Institute of Dental & Craniofacial Research | 2025 | $583,289 | July 1, 2025 | March 31, 2030 | MANZANO, MARK | reporter.nih.gov |
| Deep Sequencing of Relapse and Refractory Hodgkin Lymphoma Genomes: A Study of Tumor Biology and Evolution | NIH | National Cancer Institute | 2023 to 2025 | $583,092 | September 1, 2023 | August 31, 2026 | GOMEZ, FELICIA | reporter.nih.gov |
| The MYC Transcription Factor Network and the Path to Cancer | NIH | National Cancer Institute | 2021 | $576,145 | September 1, 2018 | March 31, 2022 | EISENMAN, ROBERT NEIL | reporter.nih.gov |
| Oligomannose antigens as conserved immunological targets of Non-Hodgkin lymphomas | NIH | National Cancer Institute | 2021 to 2022 | $575,838 | July 1, 2021 | June 30, 2025 | WANG, DENONG | reporter.nih.gov |
| A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia | NIH | National Cancer Institute | 2021 | $575,010 | June 12, 2013 | March 31, 2022 | RADER, CHRISTOPH | reporter.nih.gov |
| Molecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNA | NIH | National Cancer Institute | 2021 to 2023 | $573,912 | August 1, 2019 | April 30, 2025 | KURTZ, DAVID MATTHEW | reporter.nih.gov |
| Dynamic Analysis of Tumor and Microenvironment in Patients Undergoing Immunotherapy | NIH | National Cancer Institute | 2022 to 2024 | $570,611 | September 1, 2020 | August 31, 2025 | SHREE, TANAYA | reporter.nih.gov |
| Investigating personalized approaches to de-intensify therapy for nodular lymphocyte-predominant Hodgkin lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $569,568 | August 1, 2024 | July 31, 2029 | BINKLEY, MICHAEL S | reporter.nih.gov |
| Studies on Viral Enhancer for Latency-Lytic Switch | NIH | National Cancer Institute | 2025 | $564,698 | January 1, 2025 | December 31, 2029 | IZUMIYA, YOSHIHIRO | reporter.nih.gov |
| A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia | NIH | National Cancer Institute | 2022 | $563,511 | June 12, 2013 | March 31, 2024 | SHEN, BEN | reporter.nih.gov |
| Local nano-immune modulation for the systemic treatment of lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $551,674 | August 1, 2024 | July 31, 2029 | LIN, ADAM YUH | reporter.nih.gov |
| CD25-mediated feedback control of BCR-signaling and its oncogenic mimics | NIH | National Cancer Institute | 2021 to 2022 | $549,899 | January 1, 2021 | May 31, 2023 | MÜSCHEN, MARKUS | reporter.nih.gov |
| The role of catecholamines in immunotoxicity and tumor response of adoptive T cell therapy in cancer | NIH | National Cancer Institute | 2021 to 2022 | $540,384 | July 1, 2018 | June 30, 2023 | STAEDTKE, VERENA | reporter.nih.gov |
| (PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia | NIH | National Cancer Institute | 2021 | $538,977 | May 11, 2017 | April 30, 2022 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Epstein-Barr Virus Nuclear Protein B Cell Growth Transformation | NIH | National Cancer Institute | 2021 | $532,500 | June 1, 1987 | July 31, 2022 | ZHAO, BO | reporter.nih.gov |
| The Role of PIAS1 in EBV Biology | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $524,616 | May 13, 2019 | April 30, 2025 | LI, RENFENG | reporter.nih.gov |
| Engineered Monothiol Thioredoxin for Treatment of Radiation Induced Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $508,988 | September 24, 2025 | August 31, 2026 | HEIFETZ, PETER B | reporter.nih.gov |
| Role of FBXO45 in Diffuse Large B Cell Lymphoma Pathogenesis | NIH | National Cancer Institute | 2021 to 2022 | $498,186 | July 3, 2019 | July 31, 2022 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Role of chromatin remodeling complex BAF in immunity and lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $498,000 | March 1, 2020 | August 31, 2027 | BARISIC, DARKO | reporter.nih.gov |
| Characterization of TRPC6 to predict and prevent chemotherapy-related heart failure | NIH | National Heart, Lung, and Blood Institute | 2022 | $497,637 | September 22, 2022 | August 31, 2024 | NORTON, NADINE | reporter.nih.gov |
| (PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairment | NIH | National Cancer Institute | 2021 | $492,343 | September 15, 2017 | July 31, 2023 | ST CLAIR, DARET K | reporter.nih.gov |
| Systematic CRISPR Analysis of EBV Lymphoma Resistance Pathways to Natural Killer Cell Lysis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $492,250 | July 5, 2024 | May 31, 2026 | GEWURZ, BENJAMIN ELISON | reporter.nih.gov |
| Role of DNA sensing pathways in KSHV associated cancers | NIH | National Cancer Institute | 2021 to 2022 | $486,205 | July 1, 2020 | June 30, 2024 | MA, ZHE | reporter.nih.gov |
| Radioimmunotherapy Combinations for B-cell Malignancy | NIH | National Cancer Institute | 2021 to 2022 | $484,621 | January 1, 1998 | March 31, 2022 | GREEN, DAMIAN J. | reporter.nih.gov |
| Function of TCF-1 in antagonizing malignancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $484,000 | August 1, 2021 | July 31, 2023 | SUN, ZUOMING | reporter.nih.gov |
| Genomic Analysis of Cutaneous CD30+ Lymphoproliferative Disorders | NIH | National Cancer Institute | 2022 to 2023 | $482,803 | February 1, 2022 | January 31, 2025 | SONG, JOO | reporter.nih.gov |
| Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi | NIH | Fogarty International Center | 2021 to 2023 | $482,493 | June 1, 2019 | April 30, 2026 | WESTMORELAND, KATHERINE DOUGLAS | reporter.nih.gov |
| Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $481,818 | January 20, 2025 | December 31, 2029 | WITKOWSKI, MATTHEW | reporter.nih.gov |
| Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint | NIH | National Cancer Institute | 2023 to 2025 | $481,596 | September 19, 2023 | August 31, 2028 | WAGNER-JOHNSTON, NINA DELANEY | reporter.nih.gov |
| Building clinically faithful ex vivo indolent lymphoma models for personalized therapy | NIH | National Cancer Institute | 2021 to 2022 | $476,454 | August 17, 2021 | July 31, 2024 | WANG, Y. LYNN | reporter.nih.gov |
| Control mechanisms of 5-hydroxymethylcytosine metabolism in human cells | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $475,533 | September 1, 2023 | July 31, 2027 | KIM, HAEYOUNG | reporter.nih.gov |
| Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute | NIH | National Cancer Institute | 2023 to 2025 | $469,809 | September 22, 2023 | August 31, 2028 | COHEN, JONATHON B. | reporter.nih.gov |
| Aging, Sex Bias, and CD8 T Cell Exhaustion in Salivary Gland Inflammation | NIH | National Institute of Dental & Craniofacial Research | 2025 | $468,875 | September 19, 2025 | September 18, 2027 | BAGAVANT, HARINI | reporter.nih.gov |
| Communicating the Gist of Prognosis: An intervention to improve prognostic understanding in advanced lymphoma | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2023 | $465,650 | September 25, 2022 | June 30, 2025 | MCCONNELL, KELLY | reporter.nih.gov |
| (PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy | NIH | National Cancer Institute | 2021 | $465,400 | August 16, 2017 | July 31, 2022 | DIANTONIO, AARON | reporter.nih.gov |
| Targeted Therapies for Richters Transformation | NIH | National Cancer Institute | 2021 | $463,172 | February 7, 2017 | January 31, 2022 | LAPALOMBELLA, ROSA | reporter.nih.gov |
| E2A/HEB MEDIATED TRANSCRIPTIONAL REGULATION IN T CELL DEVELOPMENT | NIH | National Institute of General Medical Sciences | 2021 | $455,072 | August 1, 1999 | December 31, 2022 | CHAN, FRANCIS KAMING | reporter.nih.gov |
| Targeting transducin Beta-like protein 1 in mantle cell lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $454,092 | March 1, 2018 | February 28, 2023 | ALINARI, LAPO | reporter.nih.gov |
| Targeting EBV's Deubiquitinating Activity for Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $453,750 | July 17, 2024 | May 31, 2027 | WHITEHURST, CHRISTOPHER BENTON | reporter.nih.gov |
| Defining the impact of mutational drivers on the immune microenvironment of CLL | NIH | National Cancer Institute | 2022 to 2023 | $453,523 | February 1, 2022 | January 31, 2024 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Cardiopulmonary function and cerebral blood flow in Hodgkin Lymphoma survivors | NIH | National Cancer Institute | 2024 to 2025 | $452,634 | January 8, 2024 | December 31, 2026 | PHILLIPS, NICHOLAS S | reporter.nih.gov |
| Rescue T cell aging to improve CAR T cell production for elderly cancer patients | NIH | National Institute on Aging | 2025 | $451,000 | September 1, 2025 | August 31, 2027 | WU, TUOQI | reporter.nih.gov |
| Epstein-Barr virus nuclear antigen 2 in transcription regulation | NIH | National Institute of Dental & Craniofacial Research | 2025 | $450,462 | August 13, 2025 | May 31, 2030 | WANG, CHONG | reporter.nih.gov |
| AIDS malignancy-associated human herpesvirus 8 viral interferon factor regulation of lytic-trigger and pathogenesis-associated viral RTA and vIL-6 proteins | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $450,313 | February 24, 2023 | January 31, 2025 | NICHOLAS, JOHN | reporter.nih.gov |
| Cell-free DNA-Based Analysis for Diagnosis, Monitoring and Optimization of Therapy for Patients with Primary Central Nervous System Lymphomas | NIH | National Center for Advancing Translational Sciences | 2022 to 2023 | $450,312 | September 15, 2022 | July 31, 2025 | BETTEGOWDA, CHETAN | reporter.nih.gov |
| KDR/VEGFR2 regulation of HTLV-1 oncogenesis and viral gene expression | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $446,490 | April 18, 2022 | March 31, 2025 | HARHAJ, EDWARD W | reporter.nih.gov |
| Roles of p53-Regulated Pro-Survival Signals in Carcinogenesis by HTLV-1 and High-Risk Subtype HPVs | NIH | National Cancer Institute | 2023 | $445,500 | December 13, 2022 | November 30, 2025 | HARROD, ROBERT L. | reporter.nih.gov |
| A Rabbit Model of Epstein-Barr Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $443,603 | June 1, 2022 | May 31, 2025 | SAMPLE, CLARE E | reporter.nih.gov |
| Elucidating the role of the Branched Chain Aminotransferases (BCATc and BCATm) as novel metabolic checkpoints of anti-lymphoma T cell immunity | NIH | National Cancer Institute | 2021 | $443,548 | August 16, 2021 | July 31, 2025 | ANANIEVA-STOYANOVA, ELITSA ANTONOVA | reporter.nih.gov |
| Role of LC3B in Host Defense against Human Herpesvirus 8 Lytic Replication | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $442,944 | January 16, 2024 | November 30, 2025 | CHOI, YOUNG BONG | reporter.nih.gov |
| Identifying Recurrent Non-Hodgkin Lymphoma in Electronic Health Data | NIH | National Cancer Institute | 2022 | $442,176 | September 14, 2022 | March 31, 2026 | EPSTEIN, MARA MEYER | reporter.nih.gov |
| Antagonistic actions of IRF4 and BACH2 in regulating Germinal Center B cell fates and promoting Lymphomagenesis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $441,098 | July 23, 2025 | June 30, 2027 | MONDELLO, PATRIZIA | reporter.nih.gov |
| From friend to foe: proviral role of IRF-3 in chronic gammaherpesvirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $439,665 | January 19, 2024 | November 30, 2026 | TARAKANOVA, VERA L. | reporter.nih.gov |
| Reversing immune evasion and enhancing immune detection with topical resiquimod | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $438,084 | September 7, 2018 | July 31, 2023 | CLARK, RACHAEL ANN | reporter.nih.gov |
| Informatics Tools for Quantitative Digital Pathology Profiling and Integrated Prognostic Modeling | NIH | National Cancer Institute | 2021 | $437,968 | June 12, 2018 | May 31, 2023 | COOPER, LEE | reporter.nih.gov |
| Development of antigen multimers for CAR T cell detection and functional profiling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $437,156 | June 9, 2023 | May 31, 2025 | HUANG, JUN | reporter.nih.gov |
| Characterizing single cell states of activated and transformed B cells in rhesus macaque models | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $433,852 | March 2, 2023 | February 28, 2026 | SKALSKY, REBECCA L | reporter.nih.gov |
| Single-Cell Transcriptome & Effect of Immune Checkpoint Therapy on Kaposi Sarcoma | NIH | National Cancer Institute | 2021 to 2022 | $433,125 | June 3, 2021 | May 31, 2025 | RATNER, LEE | reporter.nih.gov |
| Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $432,778 | August 9, 2019 | March 31, 2022 | MCGUIRE, ANDREW | reporter.nih.gov |
| Functional state of CD8+ T cell immunity in adult T-cell leukemia/lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $431,970 | April 4, 2024 | March 31, 2026 | YE, BIHUI HILDA | reporter.nih.gov |
| Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi | NIH | Fogarty International Center | 2021 to 2023 | $431,799 | September 16, 2019 | June 30, 2024 | PAINSCHAB, MATTHEW SCOTT | reporter.nih.gov |
| RTA-Induced Ubiquitination in KSHV: A CURE-Based Approach to Identify Novel Targets and Small Molecule Inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $430,285 | February 1, 2025 | January 31, 2028 | EHRLICH, ELANA S | reporter.nih.gov |
| Microscale System for Functional T Cell Transcriptomics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $430,088 | December 16, 2020 | November 30, 2025 | KAM, LANCE C | reporter.nih.gov |
| Epstein-Barr Virus Entry into Epithelial Cells | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $429,534 | June 3, 2024 | April 30, 2026 | LONGNECKER, RICHARD M | reporter.nih.gov |
| Development of iPSC-derived iNKT cells to promote hematopoietic engraftment | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $427,625 | June 1, 2022 | May 31, 2025 | GUMPERZ, JENNY E. | reporter.nih.gov |
| Humanizing CXCL13 and CXCR5 in mice | NIH | National Cancer Institute | 2022 to 2023 | $426,770 | January 1, 2022 | December 31, 2023 | LOLIS, ELIAS | reporter.nih.gov |
| Adoptive Cellular Therapy of T Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $425,986 | July 1, 2021 | December 31, 2023 | KATZ, SAMUEL G | reporter.nih.gov |
| Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphoma | NIH | National Cancer Institute | 2021 | $423,680 | January 1, 2017 | December 31, 2022 | JAMES, RICHARD GOFF | reporter.nih.gov |
| Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas | NIH | National Cancer Institute | 2023 to 2025 | $421,023 | March 6, 2023 | February 29, 2028 | STEPHENS, DEBORAH | reporter.nih.gov |
| Lytic viral genes in the pathogenesis of oncogenic gammaherpesviruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $420,335 | June 23, 2025 | May 31, 2027 | FORREST, JAMES CRAIG | reporter.nih.gov |
| Longitudinal Quality of Life and What Matters Most to Older Adults with Indolent Non-Hodgkin Lymphoma | NIH | National Institute on Aging | 2025 | $420,000 | September 15, 2025 | August 31, 2027 | TSANG, MAZIE | reporter.nih.gov |
| Understanding the in vivo impact of immunotherapies in splenic lymphoma by intravital three-photon microscopy | NIH | National Cancer Institute | 2023 to 2024 | $419,043 | February 1, 2023 | January 31, 2025 | XU, CHRIS | reporter.nih.gov |
| Translation of Noninvasive Metabolic Biomarkers to Targeted Therapy for Cancer | NIH | National Cancer Institute | 2024 to 2025 | $417,828 | January 8, 2024 | December 31, 2026 | NATH, KAVINDRA | reporter.nih.gov |
| HTLV-1 Replication/Reactivation-Induced DNA Damage: Mechanisms and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $417,621 | November 14, 2022 | October 31, 2025 | SNOW, ANDREW L | reporter.nih.gov |
| Leading NCI Clinical Trials Network research nationally and at the City of Hope Comprehensive Cancer Center | NIH | National Cancer Institute | 2024 to 2025 | $416,206 | September 1, 2024 | August 31, 2029 | HERRERA, ALEX F. | reporter.nih.gov |
| Synthetic rocaglates as promising therapeutic agents for aggressive hematological malignancies | NIH | National Cancer Institute | 2021 to 2022 | $415,248 | February 8, 2021 | January 31, 2024 | FU, KAI | reporter.nih.gov |
| The Regulatory R-loops in Pluripotency, Early Development, and Tissue Homeostasis | NIH | National Institute of General Medical Sciences | 2024 | $411,250 | July 5, 2024 | April 30, 2029 | HUANG, XIN | reporter.nih.gov |
| A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma | NIH | National Cancer Institute | 2023 to 2024 | $408,498 | July 7, 2023 | June 30, 2025 | WINTER, STUART SHELDON | reporter.nih.gov |
| Genetic Biomarkers for Risk of CLL Progression among high-count MBLs | NIH | National Cancer Institute | 2021 to 2022 | $406,219 | January 1, 2021 | September 30, 2023 | SLAGER, SUSAN L | reporter.nih.gov |
| A combination strategy to target pathophysiology of chronic lymphocytic leukemia | NIH | National Cancer Institute | 2023 to 2024 | $405,184 | February 1, 2023 | December 31, 2025 | GANDHI, VARSHA | reporter.nih.gov |
| Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma | NIH | National Cancer Institute | 2022 to 2023 | $405,044 | January 1, 2022 | December 31, 2024 | KUHNS, MICHAEL S | reporter.nih.gov |
| Development of pHLIP-phosphoantigen conjugates for lymphoma therapy | NIH | National Cancer Institute | 2023 to 2024 | $402,682 | April 1, 2023 | March 31, 2026 | WIEMER, ANDREW J | reporter.nih.gov |
| Development of a novel antibody-drug conjugate for treating T-cell lymphoma. | NIH | National Cancer Institute | 2022 | $402,680 | September 19, 2022 | August 31, 2024 | LIN, FENG C | reporter.nih.gov |
| Viral mechanism for engaging lytic cycle promoting host transcription factors | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $402,150 | July 23, 2025 | June 30, 2027 | PAPP, BERNADETT | reporter.nih.gov |
| Anti-nucleolin aptamer AS1411: Applications in Kaposi's Sarcoma Associated Herpes Virus (KSHV) biology | NIH | National Cancer Institute | 2023 to 2024 | $401,115 | January 1, 2023 | December 31, 2025 | SHARMA-WALIA, NEELAM | reporter.nih.gov |
| Role of Protein Kinase C Mutations in Adult T-Cell Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $400,554 | January 1, 2021 | June 30, 2024 | RATNER, LEE | reporter.nih.gov |
| Interaction of HTLV-1 Tax & Hbz in Transformation | NIH | National Cancer Institute | 2021 to 2022 | $400,554 | May 10, 2021 | April 30, 2024 | RATNER, LEE | reporter.nih.gov |
| Automated molecular diagnosis on fine needle aspirates (FNA) | NIH | National Cancer Institute | 2021 | $400,000 | August 1, 2021 | January 31, 2024 | KELLEY, LAURA E | reporter.nih.gov |
| TOPIC 414 : SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY | NIH | National Cancer Institute | 2021 | $399,962 | August 1, 2021 | July 31, 2022 | SIMON, ANNA | reporter.nih.gov |
| Functional signatures of post-infusion CAR T cells for early indication of patient response | NIH | National Cancer Institute | 2025 | $399,625 | September 1, 2025 | August 31, 2027 | BERDEAUX, REBECCA L | reporter.nih.gov |
| Discovery of inhibitors of EBV lytic cycle inducing protein ZTA for therapeutic development | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $399,278 | August 16, 2022 | July 31, 2024 | YANO, TAKAHIRO | reporter.nih.gov |
| AVM0703 combined with Non-Hodgkin's Lymphoma standard of care to enhance complete response rates without additional toxicities | NIH | National Cancer Institute | 2022 | $399,193 | August 5, 2022 | October 31, 2023 | DEISHER, THERESA | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Ohio State University | Columbus, OH | 21 | $48.7 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 23 | $35.8 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 15 | $35.7 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 19 | $31.3 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 22 | $25.5 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 20 | $24.6 million | 0 | $0 |
| Yale University | New Haven, CT | 13 | $24.1 million | 0 | $0 |
| Stanford University | Stanford, CA | 21 | $22.7 million | 0 | $0 |
| Midwest Research Institute | Kansas City, MO | 1 | $22.6 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 15 | $21.8 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 18 | $18.7 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 14 | $18.7 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 9 | $15.3 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 13 | $15.1 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 14 | $14.7 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 8 | $14.5 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 15 | $13.6 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 7 | $12.5 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 11 | $12.5 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 7 | $12.1 million | 0 | $0 |
| Washington University | Saint Louis, MO | 14 | $11.9 million | 0 | $0 |
| Duke University | Durham, NC | 11 | $11.6 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 7 | $11.5 million | 0 | $0 |
| University of Florida | Gainesville, FL | 14 | $11.4 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 7 | $11.2 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 9 | $11.1 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 7 | $8.2 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 7 | $8 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 5 | $7.9 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 4 | $7.6 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 6 | $7.5 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 4 | $7.3 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 11 | $7.2 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 4 | $7.2 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 8 | $7.1 million | 0 | $0 |
| Boston Immune Technologies and Therapeutics, Inc. | Winchester, MA | 1 | $6.4 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 5 | $6.2 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 6 | $5.8 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 8 | $5.7 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 3 | $5.5 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 5 | $5.3 million | 0 | $0 |
| Rockefeller University | New York, NY | 3 | $5 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 5 | $4.8 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 4 | $4.8 million | 0 | $0 |
| Broad Institute, Inc. | Cambridge, MA | 4 | $4.7 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 3 | $4.6 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 3 | $4.6 million | 0 | $0 |
| Feinstein Institute for Medical Research | Manhasset, NY | 3 | $4.6 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 3 | $4.5 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 3 | $4.4 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 7 | $4.1 million | 0 | $0 |
| Univ of Arkansas for Med Scis | Little Rock, AR | 8 | $4.1 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 4 | $4 million | 0 | $0 |
| University of California at Davis | Davis, CA | 6 | $3.6 million | 0 | $0 |
| Tufts Medical Center | Boston, MA | 2 | $3.5 million | 0 | $0 |
| Oklahoma Medical Research Foundation | Oklahoma City, OK | 2 | $3.4 million | 0 | $0 |
| Avm Biotechnology, LLC | Seattle, WA | 3 | $3.4 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 6 | $3.3 million | 0 | $0 |
| March Biosciences INC | Houston, TX | 2 | $3.1 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 2 | $2.8 million | 0 | $0 |
| Emory University | Atlanta, GA | 7 | $2.8 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 2 | $2.8 million | 0 | $0 |
| George Washington University | Washington, DC | 1 | $2.8 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 2 | $2.7 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 3 | $2.7 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 1 | $2.7 million | 0 | $0 |
| International Agency for Res on Cancer | Lyon | 1 | $2.7 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 3 | $2.6 million | 0 | $0 |
| Public Health Institute | Oakland, CA | 1 | $2.5 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 3 | $2.5 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 3 | $2.4 million | 0 | $0 |
| New York Genome Center | New York, NY | 1 | $2.4 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 1 | $2.3 million | 0 | $0 |
| University of South Florida | Tampa, FL | 2 | $2.3 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 2 | $2.3 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 4 | $2.3 million | 0 | $0 |
| University of Chicago | Chicago, IL | 4 | $2.3 million | 0 | $0 |
| Mayo Clinic Jacksonville | Jacksonville, FL | 2 | $2.3 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 2 | $2.2 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 4 | $2.2 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 3 | $2.1 million | 0 | $0 |
| Texas A&m University Health Science CTR | College Station, TX | 2 | $2.1 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 1 | $2.1 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 2 | $2.1 million | 0 | $0 |
| Sonoval LLC | Gaithersburg, MD | 1 | $2 million | 0 | $0 |
| Cytoagents, Inc. | Pittsburgh, PA | 1 | $2 million | 0 | $0 |
| Mustang Bio, Inc. | Worcester, MA | 1 | $2 million | 0 | $0 |
| Cellectar Biosciences, Inc. | Florham Park, NJ | 1 | $2 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 1 | $1.9 million | 0 | $0 |
| Luminary Therapeutics, Inc. | Minneapolis, MN | 1 | $1.9 million | 0 | $0 |
| University of Connecticut | Storrs, CT | 2 | $1.8 million | 0 | $0 |
| Raiz Diagnostics, Inc. | Boston, MA | 1 | $1.8 million | 0 | $0 |
| Actinium Pharmaceuticals, Inc. | New York, NY | 1 | $1.7 million | 0 | $0 |
| University of California-Riverside | Riverside, CA | 1 | $1.7 million | 0 | $0 |
| Augusta University | Augusta, GA | 2 | $1.6 million | 0 | $0 |
| University of Rochester | Rochester, NY | 3 | $1.6 million | 0 | $0 |
| Stinginn, LLC | Miami, FL | 2 | $1.6 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 2 | $1.6 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 2 | $1.4 million | 0 | $0 |
| Marker Therapeutics, Inc. | Houston, TX | 1 | $1.3 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 318 | $180,283,034 | 0 | $0 |
| 2024 | 339 | $163,432,668 | 0 | $0 |
| 2023 | 352 | $166,238,814 | 0 | $0 |
| 2022 | 372 | $161,287,876 | 0 | $0 |
| 2021 | 327 | $144,426,274 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.